

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US2005/007410

International filing date: 07 March 2005 (07.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/550,268  
Filing date: 05 March 2004 (05.03.2004)

Date of receipt at the International Bureau: 27 July 2006 (27.07.2006)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1493637

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*July 18, 2006*

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/550,268

FILING DATE: *March 05, 2004*

RELATED PCT APPLICATION NUMBER: PCT/US05/07410

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US60/550,268*



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

**PATENT**  
**ARCD:405USP1**

**PROVISIONAL**  
**APPLICATION FOR UNITED STATES LETTERS PATENT**  
**for**  
**METHODS AND COMPOSITIONS RELATING TO THE**  
**PHARMACOGENETICS OF ABCC2 GENE VARIANTS**  
**by**  
**Mark J. Ratain**  
**Federico Innocenti**  
**Deanna L. Kroetz**  
**and**  
**Samir Undevia**

|                             |                 |
|-----------------------------|-----------------|
| CERTIFICATE OF EXPRESS MAIL |                 |
| Express Mail No.:           | EV 414834592 US |
| Date of Deposit:            | March 5, 2004   |

## **BACKGROUND OF THE INVENTION**

The government may own rights in the present invention pursuant to grant number GM61393 from the National Institutes of Health.

### **1. Field of the Invention**

The present invention relates generally to the fields of molecular genetics, pharmacogenetics, and cancer therapy. In particular, the present invention is directed to methods and compositions for detecting polymorphisms and correlating the presence or absence of certain polymorphisms with toxic effects of chemotherapies. More specifically, the present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2 gene and correlating these polymorphisms with toxic effects of ABCC2 substrates, as well as evaluating the risk of an individual for developing toxicity to an ABCC2 substrate. In some embodiments, the invention concerns methods and compositions for predicting or anticipating the level of toxicity caused by an ABCC2 substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient. Alterations in suggested therapy may ensue if a toxicity risk is assessed.

20

### **2. Description of Related Art**

ATP-binding cassette (ABC) genes represent the largest family of transmembrane proteins that bind ATP and use the energy to drive the transport of various molecules across cell membranes. The products of the ABC genes are known to influence oral absorption and disposition of a wide variety of drugs and play a role in the resistance of malignant cells to anticancer agents (Sparreboom *et al.*, 2000).

ABCC2, a member of the ABC gene family, functions as the major exporter of organic anions from the liver into the bile. In addition, ABCC2 is expressed on the apical membrane of epithelial cells such as enterocytes, renal proximal tubule epithelia, and gall bladder epithelia. ABCC2 is also expressed in some tumor tissues such as ovarian carcinoma, colorectal carcinoma, leukemia, mesothelioma, and hepatocarcinoma; and it

30

has been suggested that tumor cells overexpressing ABCC2 acquire multidrug resistance (MDR) (Borst *et al.* (1999); Borst *et al.* (2000)).

ABCC2 substrates include intracellularly formed glucuronide and reduced glutathione (GSH)—conjugates of clinically important drugs (Suzuki *et al.*, 1998). In  
5 addition, ABCC2 is also involved in the biliary excretion of non-conjugated anionic drugs such as irinotecan (CPT-11).

Irinotecan is an antineoplastic drug used in the treatment of colon cancer. Irinotecan hydrolysis by carboxylesterase-2 (CES-2) is responsible for its activation to SN-38 (7-ethyl-10-hydroxycamptothecin), a topoisomerase I inhibitor of much higher  
10 potency than irinotecan. The main inactivating pathway of irinotecan is the biotransformation of active SN-38 into inactive SN-38 glucuronide (SN-38G) by UDP-glucuronosyltransferase 1A1 (UGT1A1) (Iyer *et al.*, 1998).

Despite its efficacy in treating metastatic colon cancer and its broad spectrum of activity in other tumor types, irinotecan treatment is associated with significant toxicity.  
15 The main severe toxicities of irinotecan are delayed diarrhea and myelosuppression. In the early single agent trials, grade 3-4 diarrhea occurred in about one third of patients and was dose limiting (Negoro *et al.*, 1991; Rothenberg *et al.*, 1993). Its frequency varies from study to study and is also schedule dependent. The frequency of grade 3-4 diarrhea in the three-weekly regimen (19%) is significantly lower compared to the weekly  
20 schedule (36%, Fuchs *et al.*, 2003). In addition to diarrhea, grade 3-4 neutropenia is also a common adverse event, with about 30-40% of the patients experiencing it in both weekly and three-weekly regimens (Fuchs *et al.*, 2003; Vanhoefer *et al.*, 2001). Fatal events during irinotecan treatment have been reported. A high mortality rate of 5.3% and 1.6% was reported in the weekly and three-weekly single agent irinotecan regimens,  
25 respectively (Fuchs *et al.*, 2003).

Interpatient differences in systemic formation of SN-38G have been shown to have clear clinical consequences in patients treated with irinotecan. Patients with higher glucuronidation of SN-38 are more likely to be protected from the dose limiting toxicity of diarrhea in the weekly schedule (Gupta *et al.*, 1994).

30 Improved methods and compositions for the evaluation of risk for irinotecan toxicity in an individual are still needed. Clearance of irinotecan and its metabolites by

ABCC2 represents a mechanism to protect patients from the toxic effects. However, the problem of identifying the effects of various polymorphisms on drug clearance by ABCC2 remains. Resolving these problems would provide novel methods and compositions for the evaluation of risk for toxicity to irinotecan as well as for numerous other drugs that are substrates for ABCC2.

### **SUMMARY OF THE INVENTION**

The present invention is based on identification and characterization of correlations between genotype of the *ABCC2* gene and phenotype relating to the activity of ABCC2. Thus, the present invention provides methods and compositions that exploit correlations between genotype and phenotype concerning ABCC2. It is contemplated that such methods and compositions have diagnostic, prognostic, and therapeutic applications.

The present invention involves methods for determining the level of ABCC2 activity in a patient. This method can be used to predict what the level of ABCC2 activity is in a patient based on genotypic analysis. In some embodiments, the method involves determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles is indicative of a normal level of ABCC2 activity.

Additional methods of the invention include a method for predicting tumor response to an anticancer agent that is an ABCC2 substrate in a cancer patient comprising determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles is indicative of a greater chance of a reduced antitumor response to the anticancer agent. The probability of a reduced antitumor response is increased with respect to persons who do not have a C at position 3972. The determination of a T on both alleles at position 3972 in the *ABCC2* gene is indicative of a greater chance of an antitumor response or of a better antitumor response than would be expected as compared to a person with a C at position 3972.

The term "antitumor response" means a response that results in a favorable therapeutic outcome with respect to a tumor. Examples of such an outcome include, but are not limited to, reduction in tumor size, retardation of tumor growth or proliferation, inhibition of metastasis, reduction in number of metastasis, inhibition of tumor

vasculature, inhibition of tumor growth rate, promotion of apoptosis of tumor cells, induction of tumor cell death or killing, promotion of remission of cancer growth, and extended survival. Thus, a reduced antitumor response means the patient may exhibit no response to the drug or that the response is less favorable than would be expected for someone with a TT genotype at position 3972. It will understood that the prediction of a reduced antitumor response may lead to an increased dosage (increased concentration, increased administration and/or both) and/or more aggressive treatment regimen than would have been the case for someone with the TT genotype. This altered treatment may overcome the predicted reduced antitumor response. Thus, embodiments of the invention further include adjusting dosage (concentration and/or administration (timing and/or frequency)) or route of administration of the anticancer agent or altering the treatment regimen overall. In some cases, the time between treatment regimens may be altered. In specific embodiments, the anticancer agent is irinotecan.

Other methods of the invention concern a method for determining dosage of an *ABCC2* substrate for a patient comprising: a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles indicates a higher dosage of the substrate than is indicated for a patient with a T at position 3972 in both alleles of the *ABCC2* gene. In some embodiments, the *ABCC2* substrate is selected from the group of substrates consisting of cysteinyl leukotrienes, glutathione and glutathione conjugates, glucuronide conjugates, sulfated conjugates, bile salt conjugates, bromosulfophthalein, and dibromosulfophthalein (see Table 1). Identified in Table 1 are substrates that are administered as drugs to patients. Determining the dosage of any of these drugs is specifically contemplated as part of the invention. In some cases, the dosage that would be given to a patient is modified based on the genotyping results based on methods of the invention. In certain embodiments, the substrate is irinotecan, SN-38, APC, and/or SN-38G. Methods of the invention also include prescribing a dosage of the anticancer agent, such as irinotecan, based on the determination of the sequence at position 3972 in one or both alleles of the *ABCC2* gene. It is contemplated that a patient is given a different dosage than he or she would have otherwise received had the genotyping not been performed. Thus, in some embodiments

of the invention, a typical dosage is adjusted for a particular person (individualized therapy).

Methods of the invention also include monitoring for toxicity or adverse events once the ABCC2 substrate is administered, and possibly, adjusting or modifying dosage based on the those results. Toxicity indicators or indicators of adverse events include diarrhea, neutropenic fever, other hematologic toxicities, as well as known non-hematologic toxicities.

The present invention also concerns a method for predicting a clearance rate for irinotecan in a patient. The method involves determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 in one or both alleles is indicative of a normal clearance rate for irinotecan. Again, "normal" is with respect to the level of clearance that is expected for persons with the TT haplotype at position 3972. In additional embodiments, the clearance rate is determined empirically in that patient based on techniques that are well known to those of skill in the art. Identification of a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a lower than normal clearance rate for irinotecan.

Reference to nucleotides (or residues) may be according to their well known abbreviations. A "C" refers to a cytosine; "T" refers to "thymine"; "A" refers to adenine; and, "G" refers to guanine. If mRNA is used to determine a nucleotide sequence, "U" refers to uracil. In one study, the allele frequency for the variant allele (T) at position 3972 was 38.3% in Caucasians (n=100) and 27.3% African Americans (n=100). It is understood that a C is the most common nucleotide at position 3972. Because of that and the observations discussed herein, the activity of ABCC2 will be characterized relative to the activity of ABCC2 in persons with a C at 3972. Consequently, a normalized level of activity of ABCC2 in persons with a C at 3972 will be understood as a "normal level of ABCC2 activity." Moreover, in some embodiments of the invention, identification of a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a lower than normal level of ABCC2 activity.

It will be understood that the term "determine" is used according to its ordinary and plain meaning to indicate "to ascertain definitely by observation, examination,



calculation, etc.,” according to the Oxford English Dictionary (2<sup>nd</sup> ed.). It will also be understood that the phrase “determining the sequence at position X” means that the nucleotide at that position is directly or indirectly identified. In some embodiments, the sequence at a particular position is determined, while in other embodiments, what is  
5 determined at a particular position is that a particular nucleotide is *not* at that position.

Positions are indicated by conventional numbering where a negative sign (-) refers to nucleotides upstream (5') from the transcriptional start site (+1) (these sequences are in the promoter), unless otherwise designated. Sequences in the 5' untranslated region (5' UTR) may also be referred to using a negative sign, and in these cases, the positioning  
10 is with respect to the translated portion, where the first nucleotide of a codon is understood as +1. Positions downstream of the translational start site may or may not have a plus sign (+). Furthermore, unless otherwise indicated or understood, identification of a position downstream of the transcriptional start site refers to a position with respect to only the coding region of the gene, that is, its exons and not the introns. In  
15 some instances, positions within introns are referred to and the numbering for these positions is typically with respect to that intron alone, and not the gene as a whole.

It is contemplated that in methods of the invention, one or more sequences in one or both alleles of the *ABCC2* gene is determined. In some embodiments, both alleles of the patient are evaluated, while in others, only one allele is evaluated.

20 In further embodiments of the invention, methods also include obtaining a sample from a patient and using the sample to determine the sequence at position 3972. The sample may contain blood, serum, or a tissue biopsy, as well as buccal cells, mononuclear cells, or cancer cells.

Sequences may be determined by performing or conducting a hybridization assay,  
25 an amplification assay, particularly one that is allele-specific, a sequencing or microsequencing assay.

The sequence at position 3972 may be determined directly or indirectly. A direct determination involves performing an assay with respect to that position. An indirect determination means that the sequence at position 3972 is determined based on data  
30 regarding a different position, particularly by evaluating the sequence of a position in

linkage disequilibrium (LD) with a sequence at position 3972. In some embodiments, the sequence in LD with a sequence at position 3972 is in complete linkage disequilibrium with a sequence at 3972. In additional embodiments, the position in linkage disequilibrium with the sequence at position 3972 is selected from the group consisting of positions -1549 (promoter), -1019 (promoter), -24 (5' UTR), and +27 (intron 13). In some cases, more than one position in linkage disequilibrium with the sequence at position 3972 is evaluated to determine the sequence at position 3972. Therefore, in some embodiments of the invention, a haplotype that includes position 3972 is evaluated. In these embodiments, a determination of one or more sequences in one or both alleles of a gene in the haplotype is included in methods of the invention.

In methods of the invention, in some embodiments, an additional step of administering an *ABCC2* substrate to the patient is included. Likewise, in some embodiments, the step of administering an anticancer agent to the patient is included in methods of the invention. In some cases, the amount, formulation, or timing of the administration is based on the genotypic analysis of position 3972 of the *ABCC2* gene. In some embodiments of the invention, a patient is also provided additional anticancer therapy, such as the administration of a second anticancer agent or the performance of surgery on the patient. The second anticancer agent may be chemotherapy, particularly one that is not an *ABCC2* substrate or not the same *ABCC2* substrate that was already given to the patient, radiation therapy, immunotherapy, or gene therapy.

The present invention further concerns compositions that can be used to determine the sequence at position 3972 or any other sequence in LD with it. Accordingly, the present invention concerns kits for achieving methods of the invention. In some embodiments, the kits include one or more nucleic acids for determining the sequence at position 3972 in at one or both alleles of the *ABCC2* gene. In some embodiments, the nucleic acid is a primer for amplifying the sequence at position 3972 in the *ABCC2* gene. In others, the nucleic acid is a specific hybridization probe for detecting the sequence at position 3972 in the *ABCC2* gene. Additionally, it is contemplated that the specific hybridization probe can be comprised in an oligonucleotide array or microarray.

It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein. Similarly, any embodiment discussed with respect to one aspect of the invention may be used in the context of any other aspect of the invention.

5           Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

10           The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

          The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternative are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”

15           Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

20

### **BRIEF DESCRIPTION OF THE DRAWINGS**

25           The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

**FIG. 1:** ABCC2 3972C>T variant and AUC values of irinotecan and APC.

30           **FIG. 2:** ABCC2 3972C>T variant and AUC values of SN-38 and SN-38G.

## **DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS**

The present invention provides improved methods and compositions for identifying the effects of polymorphisms in ABCC2 on the disposition of drugs and drug metabolites for the evaluation of the potential risk for drug toxicity or adverse events in an individual or patient. The development of these improved methods and compositions allows for the use of such an evaluation to optimize treatment of a patient and to lower the risk of toxicity or adverse events.

### **I. ABCC2**

ABCC2, also referred to as MRP2 and cMOAT, functions as the major exporter of organic anions from the liver into the bile. In addition, ABCC2 is expressed on the apical membrane of epithelial cells such as enterocytes, renal proximal tubule epithelia, and gall bladder epithelia. ABCC2 is also expressed in some tumor tissues such as ovarian carcinoma, colorectal carcinoma, leukemia, mesothelioma, and hepatocarcinoma; and it has been suggested that tumor cells overexpressing ABCC2 acquire multidrug resistance (MDR) (Borst *et al.* (1999); Borst *et al.* (2000)).

ABCC2 is important from a pharmacological point of view because it is involved in the clearance of several clinically important drugs. One such drug is the anticancer drug irinotecan (CPT-11).

Irinotecan is also inactivated to oxidated metabolites (including APC) by CYP3A enzymes, and is activated to SN-38, which has a 100-1,000-fold higher antitumor activity than irinotecan, by carboxylesterase-2 (CES-2). SN-38 is glucuronidated by hepatic uridine diphosphate glucuronosyltransferases (UGTs) to form SN-38 glucuronide (10O-glucuronyl-SN-38, SN-38G), which is inactive and excreted into the bile and urine although, SN-38G might be deconjugated to form SN-38 by intestinal  $\beta$ -glucuronidase enzyme (Kaneda *et al.*, 1990). Irinotecan, SN-38, and SN-38G are known substrates for ABCC2. (Suzuki *et al.* (1999); Suzuki *et al.* (1998)).

The major dose-limiting toxicities of irinotecan include diarrhea and, to a lesser extent, myelosuppression. Irinotecan-induced diarrhea can be serious and often does not respond adequately to conventional antidiarrheal agents (Takasuna *et al.*, 1995). This diarrhea may be due to direct enteric injury caused by the active metabolite, SN-38,

which has been shown to accumulate in the intestine after intra peritoneal administration of irinotecan in athymic mice (Araki *et al.*, 1993).

It has been shown that there is an inverse relationship between SN-38 glucuronidation rates and severity of diarrheal incidences in patients treated with increasing doses of Irinotecan (Gupta *et al.*, 1994). These findings indicate that glucuronidation of SN-38 protects against Irinotecan-induced gastrointestinal toxicity. Therefore, differential rates of SN-38 glucuronidation among subjects may explain the considerable inter-individual variation in the pharmacokinetic parameter estimates and toxicities observed after treatment with anti-cancer drugs or exposure to xenobiotics (Gupta *et al.*, 1994; Gupta *et al.*, 1997).

The present invention demonstrates that the synonymous 3972C>T (exon 28) in ABCC2 is correlated with AUC (area under the curve) for irinotecan ( $p=0.02$ ), APC ( $p<0.0001$ ), APC/irinotecan ratio ( $p<0.0001$ ), SN-38G ( $p\leq 0.001$ ), and SN-38G/SN-38 ( $p\leq 0.001$ ). Furthermore, the TT 3972 genotype was associated with higher AUC of irinotecan ( $p=0.02$ ), APC ( $p<0.0001$ ), and SN-38G ( $p<0.0001$ ) compared to CT and CC patients. The phenotypic effect of 3972C>T was previously unknown, and identifies 3972C>T as a variant potentially affecting ABCC2 activity and suggests its biological function and clinical relevance for ABCC2 substrates. Thus, the present invention provides improved methods and compositions for evaluating the disposition of drugs and drug metabolites, and for evaluating the potential risk for drug toxicity in an individual or patient. The development of these improved methods and compositions allows for the use of such an evaluation to optimize treatment of a patient and to lower the risk of toxicity.

AUC is a measure of how much drug reaches the bloodstream in a set period of time. AUC is calculated by plotting drug blood concentration at various times over a specified period of time, usually 24 hours, and then measuring the area under the curve. AUC has a number of important uses in toxicology, biopharmaceutics, and pharmacokinetics. It is understood to be the time course or exposure of the patient to the drug.

The metabolism of irinotecan is merely illustrative of the present invention; the metabolism of other ABCC2 substrates is also contemplated. A summary of ABCC2 substrates is provided in Table 1 below. The table includes ABCC2 drug substrates.

5

**Table 1. ABCC2 Substrates**

|   |
|---|
| <b>Cysteinyl Leukotrienes</b><br>LTC <sub>4</sub><br>LTD <sub>4</sub><br>LTE <sub>4</sub><br>N-acetylated LTE <sub>4</sub>  |
| <b>GSH and GSH-Conjugates of Organic Compounds</b><br>Reduced glutathione (GSH)<br>Oxidized glutathione (GSSG)<br>2,4-dinitrophenol-S-glutathione<br>Glutathione-bimane<br>GSH Conjugate of bromosulfophthalein<br>GSH Conjugate of bromoisovalerylurea<br>GSH Conjugate of N-ethylmaleimide<br>GSH Conjugate of ethacrynic acid<br>GSH Conjugate of $\alpha$ -naphthylisothiocyanate<br>GSH Conjugate of methylfluoroscein<br>GSH Conjugate of prostaglandin A1<br>GSH Conjugate of (+)-anti-benzo[a]pyrene-7,8-diol-9,10-epoxide<br>GSH Conjugate of 4-hydroxynonenal |
| <b>GSH Conjugates of Metals</b><br>Antimony<br>Arsenic<br>Bismuth<br>Cadmium<br>Copper<br>Silver<br>Zinc  |
| <b>Glucuronide Conjugates</b><br>Bilirubin monoglucuronide<br>Bilirubin diglucuronide<br>17 $\beta$ estradiol 17 $\beta$ -D-glucuronide<br>Triiodothyronine-glucuronide<br>p-nitrophenol- $\beta$ -D-glucuronide<br>1-naphytol- $\beta$ -D-glucoronide  |

E3040 glucuronide  
 SN-38 glucuronide (SN-38G)  
 Grepafloxacin glucuronide  
 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol glucuronide  
 Telmisaltan glucuronide  
 Acetaminophen glucuronide  
 Diclofenac glucuronide  
 Indomethacin glucuronide  
 Glucuronide conjugates of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine  
 Liquiritigenin glucuronide  
 Glycyrrhizin

#### **Sulfated Conjugates**

Dehydroepiandrosterone sulfate

#### **Bile Salt Conjugates**

Cholate-3-O-glucuronide  
 Lithocholate-3-O-glucuronide  
 Chenodeoxycholate-3-O-glucuronide  
 Nordeoxycholate-3-O-glucuronide  
 Nordeoxycholate-3-sulfate  
 Lithocholate-3-sulfate  
 Taurolithocholate-3-sulfate  
 Glycolithocholate-3-sulfate  
 Taurochenodeoxycholate-3-sulfate

#### **Non-Conjugated Compounds**

Bromosulphophthalein  
 Dibromosulphophthalein  
 Carboxyfluorescein  
 Reduced folates  
 Methotrexate  
 CPT-11  
 SN-38  
 Ampicillin  
 Ceftriaxone  
 Cefodizime  
 Grepafloxacin  
 Pravastatin  
 Temocaprilat  
 BQ123  
 p-aminohippuric acid  
 Fluo-3  
 Sulfinpyrazone (GSH coupled)

|   |
|---|
| Vinblastine (GSH coupled)                                     |
| 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (GSH coupled) |
| Etroposide  |
| Vincristine   |
| Doxorubicin   |
| Epirubicin  |
| Cisplatin   |

## II. NUCLEIC ACIDS

Certain embodiments of the present invention concern various nucleic acids, including amplification primers, oligonucleotide probes, and other nucleic acid elements involved in the analysis of genomic DNA. In certain aspects, a nucleic acid comprises a wild-type, a mutant, or a polymorphic nucleic acid.

The term "nucleic acid" is well known in the art. A "nucleic acid" as used herein will generally refer to a molecule (*i.e.*, a strand) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (*e.g.*, an adenine "A," a guanine "G," a thymine "T" or a cytosine "C") or RNA (*e.g.*, an A, a G, an uracil "U" or a C). The term "nucleic acid" encompass the terms "oligonucleotide" and "polynucleotide," each as a subgenus of the term "nucleic acid." The term "oligonucleotide" refers to a molecule of between about 3 and about 100 nucleobases in length. The term "polynucleotide" refers to at least one molecule of greater than about 100 nucleobases in length. A "gene" refers to coding sequence of a gene product, as well as introns and the promoter of the gene product. In addition to the *ABCC2* gene, other regulatory regions such as enhancers for *ABCC2* are contemplated as nucleic acids for use with compositions and methods of the claimed invention.

In some embodiments, nucleic acids of the invention comprise or are complementary to all or 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240,



250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 or more contiguous nucleotides of 1 (ABCC2 cDNA), SEQ ID NO:2 (ABCC2 exon 28), or SEQ ID NO:3.

These definitions generally refer to a single-stranded molecule, but in specific embodiments will also encompass an additional strand that is partially, substantially or fully complementary to the single-stranded molecule. Thus, a nucleic acid may encompass a double-stranded molecule or a triple-stranded molecule that comprises one or more complementary strand(s) or "complement(s)" of a particular sequence comprising a molecule. As used herein, a single stranded nucleic acid may be denoted by the prefix "ss", a double stranded nucleic acid by the prefix "ds", and a triple stranded nucleic acid by the prefix "ts."

In particular aspects, a nucleic acid encodes a protein, polypeptide, or peptide. In certain embodiments, the present invention concerns novel compositions comprising at least one proteinaceous molecule. As used herein, a "proteinaceous molecule," "proteinaceous composition," "proteinaceous compound," "proteinaceous chain," or "proteinaceous material" generally refers, but is not limited to, a protein of greater than about 200 amino acids or the full length endogenous sequence translated from a gene; a polypeptide of greater than about 100 amino acids; and/or a peptide of from about 3 to about 100 amino acids. All the "proteinaceous" terms described above may be used interchangeably herein.

### **1. Preparation of Nucleic Acids**

A nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production or biological production. Non-limiting examples of a synthetic nucleic acid (*e.g.*, a synthetic oligonucleotide), include a nucleic acid made by *in vitro* chemical synthesis using phosphotriester, phosphite or phosphoramidite chemistry and solid phase techniques such as described in European Patent 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler *et al.*, 1986 and

U.S. Patent 5,705,629, each incorporated herein by reference. In the methods of the present invention, one or more oligonucleotide may be used. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Patents 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

A non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCR™ (see for example, U.S. Patent 4,683,202 and U.S. Patent 4,682,195, each incorporated herein by reference), or the synthesis of an oligonucleotide described in U.S. Patent 5,645,897, incorporated herein by reference. A non-limiting example of a biologically produced nucleic acid includes a recombinant nucleic acid produced (*i.e.*, replicated) in a living cell, such as a recombinant DNA vector replicated in bacteria (see for example, Sambrook *et al.* 2001, incorporated herein by reference).

## **2. Purification of Nucleic Acids**

A nucleic acid may be purified on polyacrylamide gels, cesium chloride centrifugation gradients, chromatography columns or by any other means known to one of ordinary skill in the art (see for example, Sambrook *et al.*, 2001, incorporated herein by reference). In some aspects, a nucleic acid is a pharmacologically acceptable nucleic acid. Pharmacologically acceptable compositions are known to those of skill in the art, and are described herein.

In certain aspects, the present invention concerns a nucleic acid that is an isolated nucleic acid. As used herein, the term "isolated nucleic acid" refers to a nucleic acid molecule (*e.g.*, an RNA or DNA molecule) that has been isolated free of, or is otherwise free of, the bulk of the total genomic and transcribed nucleic acids of one or more cells. In certain embodiments, "isolated nucleic acid" refers to a nucleic acid that has been isolated free of, or is otherwise free of, bulk of cellular components or *in vitro* reaction components such as for example, macromolecules such as lipids or proteins, small biological molecules, and the like.

## **3. Nucleic Acid Segments**

In certain embodiments, the nucleic acid is a nucleic acid segment. As used herein, the term "nucleic acid segment," are fragments of a nucleic acid, such as, for a

non-limiting example, those that encode only part of a *ABCC2* gene locus or a *ABCC2* gene sequence. Thus, a "nucleic acid segment" may comprise any part of a gene sequence, including from about 2 nucleotides to the full length gene including promoter regions to the polyadenylation signal and any length that includes all the coding region.

5           Various nucleic acid segments may be designed based on a particular nucleic acid sequence, and may be of any length. By assigning numeric values to a sequence, for example, the first residue is 1, the second residue is 2, *etc.*, an algorithm defining all nucleic acid segments can be created:

$$n \text{ to } n + y$$

10       where *n* is an integer from 1 to the last number of the sequence and *y* is the length of the nucleic acid segment minus one, where *n + y* does not exceed the last number of the sequence. Thus, for a 10-mer, the nucleic acid segments correspond to bases 1 to 10, 2 to 11, 3 to 12 ... and so on. For a 15-mer, the nucleic acid segments correspond to bases 1 to 15, 2 to 16, 3 to 17 ... and so on. For a 20-mer, the nucleic segments correspond to bases  
15       1 to 20, 2 to 21, 3 to 22 ... and so on. In certain embodiments, the nucleic acid segment may be a probe or primer. As used herein, a "probe" generally refers to a nucleic acid used in a detection method or composition. As used herein, a "primer" generally refers to a nucleic acid used in an extension or amplification method or composition.

#### 4.       Nucleic Acid Complements

20       The present invention also encompasses a nucleic acid that is complementary to a nucleic acid. A nucleic acid is "complement(s)" or is "complementary" to another nucleic acid when it is capable of base-pairing with another nucleic acid according to the standard Watson-Crick, Hoogsteen or reverse Hoogsteen binding complementarity rules. As used herein "another nucleic acid" may refer to a separate molecule or a spatial  
25       separated sequence of the same molecule. In preferred embodiments, a complement is a hybridization probe or amplification primer for the detection of a nucleic acid polymorphism.

          As used herein, the term "complementary" or "complement" also refers to a nucleic acid comprising a sequence of consecutive nucleobases or semiconsecutive  
30       nucleobases (*e.g.*, one or more nucleobase moieties are not present in the molecule) capable of hybridizing to another nucleic acid strand or duplex even if less than all the

nucleobases do not base pair with a counterpart nucleobase. However, in some diagnostic or detection embodiments, completely complementary nucleic acids are preferred.

### 5     **III.     NUCLEIC ACID DETECTION**

Some embodiments of the invention concern identifying polymorphisms in *ABCC2*, correlating genotype or haplotype to phenotype, wherein the phenotype is altered *ABCC2* activity or expression, and then identifying such polymorphisms in patients who have or will be given irinotecan or other drugs or compounds that are  
10    *ABCC2* substrates. Thus, the present invention involves assays for identifying polymorphisms and other nucleic acid detection methods. Nucleic acids, therefore, have utility as probes or primers for embodiments involving nucleic acid hybridization. They may be used in diagnostic or screening methods of the present invention. Detection of nucleic acids encoding *ABCC2*, as well as nucleic acids involved in the expression or  
15    stability of *ABCC2* polypeptides or transcripts, are encompassed by the invention. General methods of nucleic acid detection methods are provided below, followed by specific examples employed for the identification of polymorphisms, including single nucleotide polymorphisms (SNPs).

#### **A.     Hybridization**

20       The use of a probe or primer of between 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 60, 70, 80, 90, or 100 nucleotides, preferably between 17 and 100 nucleotides in length, or in some aspects of the invention up to 1-2 kilobases or more in length, allows the formation of a duplex molecule that is both stable and selective. Molecules having complementary sequences over contiguous stretches greater  
25    than 20 bases in length are generally preferred, to increase stability and/or selectivity of the hybrid molecules obtained. One will generally prefer to design nucleic acid molecules for hybridization having one or more complementary sequences of 20 to 30 nucleotides, or even longer where desired. Such fragments may be readily prepared, for example, by directly synthesizing the fragment by chemical means or by introducing  
30    selected sequences into recombinant vectors for recombinant production.

Accordingly, the nucleotide sequences of the invention may be used for their ability to selectively form duplex molecules with complementary stretches of DNAs and/or RNAs or to provide primers for amplification of DNA or RNA from samples. Depending on the application envisioned, one would desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of the probe or primers for the target sequence.

For applications requiring high selectivity, one will typically desire to employ relatively high stringency conditions to form the hybrids. For example, relatively low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.10 M NaCl at temperatures of about 50°C to about 70°C. Such high stringency conditions tolerate little, if any, mismatch between the probe or primers and the template or target strand and would be particularly suitable for isolating specific genes or for detecting a specific polymorphism. It is generally appreciated that conditions can be rendered more stringent by the addition of increasing amounts of formamide. For example, under highly stringent conditions, hybridization to filter-bound DNA may be carried out in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1 x SSC/0.1% SDS at 68°C (Ausubel *et al.*, 1989).

Conditions may be rendered less stringent by increasing salt concentration and/or decreasing temperature. For example, a medium stringency condition could be provided by about 0.1 to 0.25M NaCl at temperatures of about 37°C to about 55°C, while a low stringency condition could be provided by about 0.15M to about 0.9M salt, at temperatures ranging from about 20°C to about 55°C. Under low stringent conditions, such as moderately stringent conditions the washing may be carried out for example in 0.2 x SSC/0.1% SDS at 42°C (Ausubel *et al.*, 1989). Hybridization conditions can be readily manipulated depending on the desired results.

In other embodiments, hybridization may be achieved under conditions of, for example, 50mM Tris-HCl (pH 8.3), 75mM KCl, 3mM MgCl<sub>2</sub>, 1.0mM dithiothreitol, at temperatures between approximately 20°C to about 37°C. Other hybridization conditions utilized could include approximately 10mM Tris-HCl (pH 8.3), 50mM KCl, 1.5mM MgCl<sub>2</sub>, at temperatures ranging from approximately 40°C to about 72°C.

In certain embodiments, it will be advantageous to employ nucleic acids of defined sequences of the present invention in combination with an appropriate means, such as a label, for determining hybridization. A wide variety of appropriate indicator means are known in the art, including fluorescent, radioactive, enzymatic or other ligands, such as avidin/biotin, which are capable of being detected. In preferred  
5       embodiments, one may desire to employ a fluorescent label or an enzyme tag such as urease, alkaline phosphatase or peroxidase, instead of radioactive or other environmentally undesirable reagents. In the case of enzyme tags, colorimetric indicator substrates are known that can be employed to provide a detection means that is visibly or  
10       spectrophotometrically detectable, to identify specific hybridization with complementary nucleic acid containing samples. In other aspects, a particular nuclease cleavage site may be present and detection of a particular nucleotide sequence can be determined by the presence or absence of nucleic acid cleavage.

In general, it is envisioned that the probes or primers described herein will be  
15       useful as reagents in solution hybridization, as in PCR, for detection of expression or genotype of corresponding genes, as well as in embodiments employing a solid phase. In embodiments involving a solid phase, the test DNA (or RNA) is adsorbed or otherwise affixed to a selected matrix or surface. This fixed, single-stranded nucleic acid is then subjected to hybridization with selected probes under desired conditions. The conditions  
20       selected will depend on the particular circumstances (depending, for example, on the G+C content, type of target nucleic acid, source of nucleic acid, size of hybridization probe, *etc.*). Optimization of hybridization conditions for the particular application of interest is well known to those of skill in the art. After washing of the hybridized molecules to remove non-specifically bound probe molecules, hybridization is detected,  
25       and/or quantified, by determining the amount of bound label. Representative solid phase hybridization methods are disclosed in U.S. Patents 5,843,663, 5,900,481 and 5,919,626. Other methods of hybridization that may be used in the practice of the present invention are disclosed in U.S. Patents 5,849,481, 5,849,486 and 5,851,772. The relevant portions of these and other references identified in this section of the Specification are  
30       incorporated herein by reference.

## **B. Amplification of Nucleic Acids**

Nucleic acids used as a template for amplification may be isolated from cells, tissues or other samples according to standard methodologies (Sambrook *et al.*, 2001). In certain embodiments, analysis is performed on whole cell or tissue homogenates or biological fluid samples with or without substantial purification of the template nucleic acid. The nucleic acid may be genomic DNA or fractionated or whole cell RNA. Where RNA is used, it may be desired to first convert the RNA to a complementary DNA.

The term "primer," as used herein, is meant to encompass any nucleic acid that is capable of priming the synthesis of a nascent nucleic acid in a template-dependent process. Typically, primers are oligonucleotides from ten to twenty and/or thirty base pairs in length, but longer sequences can be employed. Primers may be provided in double-stranded and/or single-stranded form, although the single-stranded form is preferred.

Pairs of primers designed to selectively hybridize to nucleic acids corresponding to the *ABCC2* gene locus (GenBank accession NT030059, incorporated herein by reference), or variants thereof, and fragments thereof are contacted with the template nucleic acid under conditions that permit selective hybridization. Depending upon the desired application, high stringency hybridization conditions may be selected that will only allow hybridization to sequences that are completely complementary to the primers. In other embodiments, hybridization may occur under reduced stringency to allow for amplification of nucleic acids that contain one or more mismatches with the primer sequences. Once hybridized, the template-primer complex is contacted with one or more enzymes that facilitate template-dependent nucleic acid synthesis. Multiple rounds of amplification, also referred to as "cycles," are conducted until a sufficient amount of amplification product is produced.

The amplification product may be detected, analyzed or quantified. In certain applications, the detection may be performed by visual means. In certain applications, the detection may involve indirect identification of the product via chemiluminescence, radioactive scintigraphy of incorporated radiolabel or fluorescent label or even via a system using electrical and/or thermal impulse signals (Affymax technology; Bellus, 1994).

A number of template dependent processes are available to amplify the oligonucleotide sequences present in a given template sample. One of the best known amplification methods is the polymerase chain reaction (referred to as PCR™) which is described in detail in U.S. Patents 4,683,195, 4,683,202 and 4,800,159, and in Innis *et al.*,  
5 1988, each of which is incorporated herein by reference in their entirety.

Another method for amplification is ligase chain reaction ("LCR"), disclosed in European Application No. 320 308, incorporated herein by reference in its entirety. U.S. Patent 4,883,750 describes a method similar to LCR for binding probe pairs to a target sequence. A method based on PCR™ and oligonucleotide ligase assay (OLA) (described  
10 in further detail below), disclosed in U.S. Patent 5,912,148, may also be used.

Alternative methods for amplification of target nucleic acid sequences that may be used in the practice of the present invention are disclosed in U.S. Patents 5,843,650, 5,846,709, 5,846,783, 5,849,546, 5,849,497, 5,849,547, 5,858,652, 5,866,366, 5,916,776, 5,922,574, 5,928,905, 5,928,906, 5,932,451, 5,935,825, 5,939,291 and 5,942,391, Great  
15 Britain Application 2 202 328, and in PCT Application PCT/US89/01025, each of which is incorporated herein by reference in its entirety. Qbeta Replicase, described in PCT Application PCT/US87/00880, may also be used as an amplification method in the present invention.

An isothermal amplification method, in which restriction endonucleases and  
20 ligases are used to achieve the amplification of target molecules that contain nucleotide 5'-[alpha-thio]-triphosphates in one strand of a restriction site may also be useful in the amplification of nucleic acids in the present invention (Walker *et al.*, 1992). Strand Displacement Amplification (SDA), disclosed in U.S. Patent 5,916,779, is another method of carrying out isothermal amplification of nucleic acids which involves multiple  
25 rounds of strand displacement and synthesis, *i.e.*, nick translation

Other nucleic acid amplification procedures include transcription-based amplification systems (TAS), including nucleic acid sequence based amplification (NASBA) and 3SR (Kwoh *et al.*, 1989; PCT Application WO 88/10315, incorporated  
herein by reference in their entirety). European Application 329 822 disclose a nucleic  
30 acid amplification process involving cyclically synthesizing single-stranded RNA



("ssRNA"), ssDNA, and double-stranded DNA (dsDNA), which may be used in accordance with the present invention.

PCT Application WO 89/06700 (incorporated herein by reference in its entirety) disclose a nucleic acid sequence amplification scheme based on the hybridization of a promoter region/primer sequence to a target single-stranded DNA ("ssDNA") followed by transcription of many RNA copies of the sequence. This scheme is not cyclic, *i.e.*, new templates are not produced from the resultant RNA transcripts. Other amplification methods include "RACE" and "one-sided PCR" (Frohman, 1990; Ohara *et al.*, 1989).

### C. Detection of Nucleic Acids

Following any amplification, it may be desirable to separate the amplification product from the template and/or the excess primer. In one embodiment, amplification products are separated by agarose, agarose-acrylamide or polyacrylamide gel electrophoresis using standard methods (Sambrook *et al.*, 2001). Separated amplification products may be cut out and eluted from the gel for further manipulation. Using low melting point agarose gels, the separated band may be removed by heating the gel, followed by extraction of the nucleic acid.

Separation of nucleic acids may also be effected by spin columns and/or chromatographic techniques known in art. There are many kinds of chromatography which may be used in the practice of the present invention, including adsorption, partition, ion-exchange, hydroxylapatite, molecular sieve, reverse-phase, column, paper, thin-layer, and gas chromatography as well as HPLC.

In certain embodiments, the amplification products are visualized, with or without separation. A typical visualization method involves staining of a gel with ethidium bromide and visualization of bands under UV light. Alternatively, if the amplification products are integrally labeled with radio- or fluorometrically-labeled nucleotides, the separated amplification products can be exposed to x-ray film or visualized under the appropriate excitatory spectra.

In one embodiment, following separation of amplification products, a labeled nucleic acid probe is brought into contact with the amplified marker sequence. The probe preferably is conjugated to a chromophore but may be radiolabeled. In another

embodiment, the probe is conjugated to a binding partner, such as an antibody or biotin, or another binding partner carrying a detectable moiety.

In particular embodiments, detection is by Southern blotting and hybridization with a labeled probe. The techniques involved in Southern blotting are well known to those of skill in the art (see Sambrook *et al.*, 2001). One example of the foregoing is described in U.S. Patent 5,279,721, incorporated by reference herein, which discloses an apparatus and method for the automated electrophoresis and transfer of nucleic acids. The apparatus permits electrophoresis and blotting without external manipulation of the gel and is ideally suited to carrying out methods according to the present invention.

Other methods of nucleic acid detection that may be used in the practice of the instant invention are disclosed in U.S. Patents 5,840,873, 5,843,640, 5,843,651, 5,846,708, 5,846,717, 5,846,726, 5,846,729, 5,849,487, 5,853,990, 5,853,992, 5,853,993, 5,856,092, 5,861,244, 5,863,732, 5,863,753, 5,866,331, 5,905,024, 5,910,407, 5,912,124, 5,912,145, 5,919,630, 5,925,517, 5,928,862, 5,928,869, 5,929,227, 5,932,413 and 5,935,791, each of which is incorporated herein by reference.

#### **D. Other Assays**

Other methods for genetic screening may be used within the scope of the present invention, for example, to detect mutations in genomic DNA, cDNA and/or RNA samples. Methods used to detect point mutations include denaturing gradient gel electrophoresis ("DGGE"), restriction fragment length polymorphism analysis ("RFLP"), chemical or enzymatic cleavage methods, direct sequencing of target regions amplified by PCR<sup>TM</sup> (see above), single-strand conformation polymorphism analysis ("SSCP") and other methods well known in the art.

One method of screening for point mutations is based on RNase cleavage of base pair mismatches in RNA/DNA or RNA/RNA heteroduplexes. As used herein, the term "mismatch" is defined as a region of one or more unpaired or mispaired nucleotides in a double-stranded RNA/RNA, RNA/DNA or DNA/DNA molecule. This definition thus includes mismatches due to insertion/deletion mutations, as well as single or multiple base point mutations.

U.S. Patent 4,946,773 describes an RNase A mismatch cleavage assay that involves annealing single-stranded DNA or RNA test samples to an RNA probe, and

subsequent treatment of the nucleic acid duplexes with RNase A. For the detection of mismatches, the single-stranded products of the RNase A treatment, electrophoretically separated according to size, are compared to similarly treated control duplexes. Samples containing smaller fragments (cleavage products) not seen in the control duplex are scored as positive.

Other investigators have described the use of RNase I in mismatch assays. The use of RNase I for mismatch detection is described in literature from Promega Biotech. Promega markets a kit containing RNase I that is reported to cleave three out of four known mismatches. Others have described using the MutS protein or other DNA-repair enzymes for detection of single-base mismatches.

Alternative methods for detection of deletion, insertion or substitution mutations that may be used in the practice of the present invention are disclosed in U.S. Patents 5,849,483, 5,851,770, 5,866,337, 5,925,525 and 5,928,870, each of which is incorporated herein by reference in its entirety.

#### **E. Specific Examples of SNP Screening Methods**

Spontaneous mutations that arise during the course of evolution in the genomes of organisms are often not immediately transmitted throughout all of the members of the species, thereby creating polymorphic alleles that co-exist in the species populations. Often polymorphisms are the cause of genetic diseases. Several classes of polymorphisms have been identified. For example, variable nucleotide type polymorphisms (VNTRs), arise from spontaneous tandem duplications of di- or trinucleotide repeated motifs of nucleotides. If such variations alter the lengths of DNA fragments generated by restriction endonuclease cleavage, the variations are referred to as restriction fragment length polymorphisms (RFLPs). RFLPs are been widely used in human and animal genetic analyses.

Another class of polymorphisms are generated by the replacement of a single nucleotide. Such single nucleotide polymorphisms (SNPs) rarely result in changes in a restriction endonuclease site. Thus, SNPs are rarely detectable restriction fragment length analysis. SNPs are the most common genetic variations and occur once every 100 to 300 bases and several SNP mutations have been found that affect a single nucleotide in a protein-encoding gene in a manner sufficient to actually cause a genetic disease. SNP

diseases are exemplified by hemophilia, sickle-cell anemia, hereditary hemochromatosis, late-onset alzheimer disease *etc.*

In context of the present invention, polymorphic mutations that affect the activity and/or level of the *ABCC2* gene product, which is responsible for the transport of numerous compounds across cell membranes, will be determined by a series of screening methods. To do this, a sample (such as blood or other bodily fluid or tissue sample) will be taken from a patient for genotype analysis. The presence or absence of SNPs will determine the ability of the screened individuals to metabolize irinotecan and other agents that are transported by *ABCC2*. According to methods provided by the invention, these results will be used to adjust and/or alter the dose of irinotecan or other agent administered to an individual in order to reduce drug side effects. In one embodiment, the presence of the 3972C>T variant in the *ABCC2* gene will be determined. The identification of a T at position 3972 on both alleles would indicate that the patient will be slower to dispose of *ABCC2* substrates (*e.g.*, irinotecan) than a patient with a C at position 3972 on one or both alleles. Thus, to minimize drug toxicity, it may be desirable to administer a lower drug dose to the patient having a T at position 3972 on both alleles.

In some embodiments, the methods and compositions of the present invention involve determining the sequence at polymorphic sites in linkage disequilibrium with the sequence at position 3972 of the *ABCC2* gene. For example, a common haplotype with the 3972 variant is one that includes two promoter variants (-1549A>G and -1019A>G) and a 5' UTR variant (-24C>T). Another haplotype including the 3972 variant and the -1549 and -1019 promoter variants is also common. Thus, in certain embodiments, the methods and compositions of the present invention comprise detecting one or more of the -1549A>G, -1019A>G, or -24C>T variants in the *ABCC2* gene. Yet another haplotype with the 3972 variant includes the -1549A>G promoter variant and an intronic variant in intron 13 (+27C>G). Thus, in certain embodiments, the methods and compositions of the present invention comprise detecting one or both of the -1549A>G or +27C>G variants in the *ABCC2* gene.

SNPs can be the result of deletions, point mutations and insertions and in general any single base alteration, whatever the cause, can result in a SNP. The greater frequency of SNPs means that they can be more readily identified than the other classes of

polymorphisms. The greater uniformity of their distribution permits the identification of SNPs "nearer" to a particular trait of interest. The combined effect of these two attributes makes SNPs extremely valuable. For example, if a particular trait (*e.g.*, inability to efficiently metabolize irinotecan) reflects a mutation at a particular locus, then any polymorphism that is linked to the particular locus can be used to predict the probability that an individual will exhibit that trait.

Several methods have been developed to screen polymorphisms and some examples are listed below. The reference of Kwok and Chen (2003) and Kwok (2001) provide overviews of some of these methods; both of these references are specifically incorporated by reference.

SNPs relating to ABCC2 can be characterized by the use of any of these methods or suitable modification thereof. Such methods include the direct or indirect sequencing of the site, the use of restriction enzymes where the respective alleles of the site create or destroy a restriction site, the use of allele-specific hybridization probes, the use of antibodies that are specific for the proteins encoded by the different alleles of the polymorphism, or any other biochemical interpretation.

#### **i) DNA Sequencing**

The most commonly used method of characterizing a polymorphism is direct DNA sequencing of the genetic locus that flanks and includes the polymorphism. Such analysis can be accomplished using either the "dideoxy-mediated chain termination method," also known as the "Sanger Method" (Sanger *et al.*, 1975) or the "chemical degradation method," also known as the "Maxam-Gilbert method" (Maxam *et al.*, 1977). Sequencing in combination with genomic sequence-specific amplification technologies, such as the polymerase chain reaction may be utilized to facilitate the recovery of the desired genes (Mullis *et al.*, 1986; European Patent Application 50,424; European Patent Application. 84,796, European Patent Application 258,017, European Patent Application. 237,362; European Patent Application. 201,184; U.S. Patents 4,683,202; 4,582,788; and 4,683,194), all of the above incorporated herein by reference.

#### **ii) Exonuclease Resistance**

Other methods that can be employed to determine the identity of a nucleotide present at a polymorphic site utilize a specialized exonuclease-resistant nucleotide

derivative (U.S. Patent. 4,656,127). A primer complementary to an allelic sequence immediately 3'-to the polymorphic site is hybridized to the DNA under investigation. If the polymorphic site on the DNA contains a nucleotide that is complementary to the particular exonucleotide-resistant nucleotide derivative present, then that derivative will be incorporated by a polymerase onto the end of the hybridized primer. Such incorporation makes the primer resistant to exonuclease cleavage and thereby permits its detection. As the identity of the exonucleotide-resistant derivative is known one can determine the specific nucleotide present in the polymorphic site of the DNA.

### iii) Microsequencing Methods

Several other primer-guided nucleotide incorporation procedures for assaying polymorphic sites in DNA have been described (Komher *et al.*, 1989; Sokolov, 1990; Syvanen 1990; Kuppuswamy *et al.*, 1991; Prezant *et al.*, 1992; Ugozzoll *et al.*, 1992; Nyren *et al.*, 1993). These methods rely on the incorporation of labeled deoxynucleotides to discriminate between bases at a polymorphic site. As the signal is proportional to the number of deoxynucleotides incorporated, polymorphisms that occur in runs of the same nucleotide result in a signal that is proportional to the length of the run (Syvanen *et al.*, 1990).

### iv) Extension in Solution

French Patent 2,650,840 and PCT Application WO91/02087 discuss a solution-based method for determining the identity of the nucleotide of a polymorphic site. According to these methods, a primer complementary to allelic sequences immediately 3'-to a polymorphic site is used. The identity of the nucleotide of that site is determined using labeled dideoxynucleotide derivatives which are incorporated at the end of the primer if complementary to the nucleotide of the polymorphic site.

### v) Genetic Bit Analysis or Solid-Phase Extension

PCT Application WO92/15712 describes a method that uses mixtures of labeled terminators and a primer that is complementary to the sequence 3' to a polymorphic site. The labeled terminator that is incorporated is complementary to the nucleotide present in the polymorphic site of the target molecule being evaluated and is thus identified. Here the primer or the target molecule is immobilized to a solid phase.

#### vi) Oligonucleotide Ligation Assay (OLA)

This is another solid phase method that uses different methodology (Landegren *et al.*, 1988). Two oligonucleotides, capable of hybridizing to abutting sequences of a single strand of a target DNA are used. One of these oligonucleotides is biotinylated while the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate. Ligation permits the recovery of the labeled oligonucleotide by using avidin. Other nucleic acid detection assays, based on this method, combined with PCR have also been described (Nickerson *et al.*, 1990). Here PCR is used to achieve the exponential amplification of target DNA, which is then detected using the OLA.

#### vii) Ligase/Polymerase-Mediated Genetic Bit Analysis

U.S. Patent 5,952,174 describes a method that also involves two primers capable of hybridizing to abutting sequences of a target molecule. The hybridized product is formed on a solid support to which the target is immobilized. Here the hybridization occurs such that the primers are separated from one another by a space of a single nucleotide. Incubating this hybridized product in the presence of a polymerase, a ligase, and a nucleoside triphosphate mixture containing at least one deoxynucleoside triphosphate allows the ligation of any pair of abutting hybridized oligonucleotides. Addition of a ligase results in two events required to generate a signal, extension and ligation. This provides a higher specificity and lower "noise" than methods using either extension or ligation alone and unlike the polymerase-based assays, this method enhances the specificity of the polymerase step by combining it with a second hybridization and a ligation step for a signal to be attached to the solid phase.

#### viii) Other Methods To Detect SNPs

Several other specific methods for SNP detection and identification are presented below and may be used as such or with suitable modifications in conjunction with identifying polymorphisms of the *ABCC2* gene in the present invention. Several other methods are also described on the SNP web site of the NCBI at the website [www.ncbi.nlm.nih.gov/SNP](http://www.ncbi.nlm.nih.gov/SNP), incorporated herein by reference.

In a particular embodiment, extended haplotypes may be determined at any given locus in a population, which allows one to identify exactly which SNPs will be redundant and which will be essential in association studies. The latter is referred to as 'haplotype tag SNPs (htSNPs)', markers that capture the haplotypes of a gene or a region of linkage disequilibrium. See Johnson *et al.* (2001) and Ke and Cardon (2003), each of which is  
5 incorporated herein by reference, for exemplary methods.

The VDA-assay utilizes PCR amplification of genomic segments by long PCR methods using TaKaRa LA Taq reagents and other standard reaction conditions. The long amplification can amplify DNA sizes of about 2,000-12,000 bp. Hybridization of  
10 products to variant detector array (VDA) can be performed by a Affymetrix High Throughput Screening Center and analyzed with computerized software.

A method called Chip Assay uses PCR amplification of genomic segments by standard or long PCR protocols. Hybridization products are analyzed by VDA, Halushka *et al.* (1999), incorporated herein by reference. SNPs are generally classified as "Certain" or "Likely" based on computer analysis of hybridization patterns. By comparison to  
15 alternative detection methods such as nucleotide sequencing, "Certain" SNPs have been confirmed 100% of the time; and "Likely" SNPs have been confirmed 73% of the time by this method.

Other methods simply involve PCR amplification following digestion with the relevant restriction enzyme. Yet others involve sequencing of purified PCR products  
20 from known genomic regions.

In yet another method, individual exons or overlapping fragments of large exons are PCR-amplified. Primers are designed from published or database sequences and PCR-amplification of genomic DNA is performed using the following conditions: 200 ng  
25 DNA template, 0.5 $\mu$ M each primer, 80 $\mu$ M each of dCTP, dATP, dTTP and dGTP, 5% formamide, 1.5mM MgCl<sub>2</sub>, 0.5U of Taq polymerase and 0.1 volume of the Taq buffer. Thermal cycling is performed and resulting PCR-products are analyzed by PCR-single strand conformation polymorphism (PCR-SSCP) analysis, under a variety of conditions, *e.g.* 5 or 10% polyacrylamide gel with 15% urea, with or without 5% glycerol.  
30 Electrophoresis is performed overnight. PCR-products that show mobility shifts are reamplified and sequenced to identify nucleotide variation.



In a method called CGAP-GAI (DEMIGLACE), sequence and alignment data (from a PHRAP.ace file), quality scores for the sequence base calls (from PHRED quality files), distance information (from PHYLIP dnadist and neighbour programs) and base-calling data (from PHRED '-d' switch) are loaded into memory. Sequences are aligned and examined for each vertical chunk ('slice') of the resulting assembly for disagreement. Any such slice is considered a candidate SNP (DEMIGLACE). A number of filters are used by DEMIGLACE to eliminate slices that are not likely to represent true polymorphisms. These include filters that: (i) exclude sequences in any given slice from SNP consideration where neighboring sequence quality scores drop 40% or more; (ii) exclude calls in which peak amplitude is below the fifteenth percentile of all base calls for that nucleotide type; (iii) disqualify regions of a sequence having a high number of disagreements with the consensus from participating in SNP calculations; (iv) removed from consideration any base call with an alternative call in which the peak takes up 25% or more of the area of the called peak; (v) exclude variations that occur in only one read direction. PHRED quality scores were converted into probability-of-error values for each nucleotide in the slice. Standard Bayesian methods are used to calculate the posterior probability that there is evidence of nucleotide heterogeneity at a given location.

In a method called CU-RDF (RESEQ), PCR amplification is performed from DNA isolated from blood using specific primers for each SNP, and after typical cleanup protocols to remove unused primers and free nucleotides, direct sequencing using the same or nested primers.

In a method called DEBNICK (METHOD-B), a comparative analysis of clustered EST sequences is performed and confirmed by fluorescent-based DNA sequencing. In a related method, called DEBNICK (METHOD-C), comparative analysis of clustered EST sequences with phred quality > 20 at the site of the mismatch, average phred quality >= 20 over 5 bases 5'-FLANK and 3' to the SNP, no mismatches in 5 bases 5' and 3' to the SNP, at least two occurrences of each allele is performed and confirmed by examining traces.

In a method identified by ERO (RESEQ), new primers sets are designed for electronically published STSs and used to amplify DNA from 10 different mouse strains. The amplification product from each strain is then gel purified and sequenced using a

standard dideoxy, cycle sequencing technique with  $^{33}\text{P}$ -labeled terminators. All the ddATP terminated reactions are then loaded in adjacent lanes of a sequencing gel followed by all of the ddGTP reactions and so on. SNPs are identified by visually scanning the radiographs.

5            In another method identified as ERO (RESEQ-HT), new primers sets are designed for electronically published murine DNA sequences and used to amplify DNA from 10 different mouse strains. The amplification product from each strain is prepared for sequencing by treating with Exonuclease I and Shrimp Alkaline Phosphatase. Sequencing is performed using ABI Prism Big Dye Terminator Ready Reaction Kit  
10 (Perkin-Elmer) and sequence samples are run on the 3700 DNA Analyzer (96 Capillary Sequencer).

            FGU-CBT (SCA2-SNP) identifies a method where the region containing the SNP were PCR amplified using the primers SCA2-FP3 and SCA2-RP3. Approximately 100 ng of genomic DNA is amplified in a 50 ml reaction volume containing a final  
15 concentration of 5mM Tris, 25mM KCl, 0.75mM  $\text{MgCl}_2$ , 0.05% gelatin, 20pmol of each primer and 0.5U of Taq DNA polymerase. Samples are denatured, annealed and extended and the PCR product is purified from a band cut out of the agarose gel using, for example, the QIAquick gel extraction kit (Qiagen) and is sequenced using dye terminator chemistry on an ABI Prism 377 automated DNA sequencer with the PCR  
20 primers.

            In a method identified as JBLACK (SEQ/RESTRICT), two independent PCR reactions are performed with genomic DNA. Products from the first reaction are analyzed by sequencing, indicating a unique FspI restriction site. The mutation is confirmed in the product of the second PCR reaction by digesting with Fsp I.

25            In a method described as KWOK(1), SNPs are identified by comparing high quality genomic sequence data from four randomly chosen individuals by direct DNA sequencing of PCR products with dye-terminator chemistry (see Kwok *et al.*, 1996). In a related method identified as KWOK(2) SNPs are identified by comparing high quality genomic sequence data from overlapping large-insert clones such as bacterial artificial  
30 chromosomes (BACs) or P1-based artificial chromosomes (PACs). An STS containing this SNP is then developed and the existence of the SNP in various populations is

confirmed by pooled DNA sequencing (see Taillon-Miller *et al.*, 1998). In another similar method called KWOK(3), SNPs are identified by comparing high quality genomic sequence data from overlapping large-insert clones BACs or PACs. The SNPs found by this approach represent DNA sequence variations between the two donor chromosomes but the allele frequencies in the general population have not yet been determined. In method KWOK(5), SNPs are identified by comparing high quality genomic sequence data from a homozygous DNA sample and one or more pooled DNA samples by direct DNA sequencing of PCR products with dye-terminator chemistry. The STSs used are developed from sequence data found in publicly available databases. Specifically, these STSs are amplified by PCR against a complete hydatidiform mole (CHM) that has been shown to be homozygous at all loci and a pool of DNA samples from 80 CEPH parents (see Kwok *et al.*, 1994).

In another such method, KWOK (OverlapSnpDetectionWithPolyBayes), SNPs are discovered by automated computer analysis of overlapping regions of large-insert human genomic clone sequences. For data acquisition, clone sequences are obtained directly from large-scale sequencing centers. This is necessary because base quality sequences are not present/available through GenBank. Raw data processing involves analyzed of clone sequences and accompanying base quality information for consistency. Finished ('base perfect', error rate lower than 1 in 10,000 bp) sequences with no associated base quality sequences are assigned a uniform base quality value of 40 (1 in 10,000 bp error rate). Draft sequences without base quality values are rejected. Processed sequences are entered into a local database. A version of each sequence with known human repeats masked is also stored. Repeat masking is performed with the program "MASKERAID." Overlap detection: Putative overlaps are detected with the program "WUBLAST." Several filtering steps followed in order to eliminate false overlap detection results, *i.e.* similarities between a pair of clone sequences that arise due to sequence duplication as opposed to true overlap. Total length of overlap, overall percent similarity, number of sequence differences between nucleotides with high base quality value "high-quality mismatches." Results are also compared to results of restriction fragment mapping of genomic clones at Washington University Genome Sequencing Center, finisher's reports on overlaps, and results of the sequence contig

building effort at the NCBI. SNP detection: Overlapping pairs of clone sequence are analyzed for candidate SNP sites with the 'POLYBAYES' SNP detection software. Sequence differences between the pair of sequences are scored for the probability of representing true sequence variation as opposed to sequencing error. This process requires the presence of base quality values for both sequences. High-scoring candidates are extracted. The search is restricted to substitution-type single base pair variations. Confidence score of candidate SNP is computed by the POLYBAYES software.

In method identified by KWOK (TaqMan assay), the TaqMan assay is used to determine genotypes for 90 random individuals. In method identified by KYUGEN(Q1), DNA samples of indicated populations are pooled and analyzed by PLACE-SSCP. Peak heights of each allele in the pooled analysis are corrected by those in a heterozygote, and are subsequently used for calculation of allele frequencies. Allele frequencies higher than 10% are reliably quantified by this method. Allele frequency = 0 (zero) means that the allele was found among individuals, but the corresponding peak is not seen in the examination of pool. Allele frequency = 0-0.1 indicates that minor alleles are detected in the pool but the peaks are too low to reliably quantify.

In yet another method identified as KYUGEN (Method1), PCR products are post-labeled with fluorescent dyes and analyzed by an automated capillary electrophoresis system under SSCP conditions (PLACE-SSCP). Four or more individual DNAs are analyzed with or without two pooled DNA (Japanese pool and CEPH parents pool) in a series of experiments. Alleles are identified by visual inspection. Individual DNAs with different genotypes are sequenced and SNPs identified. Allele frequencies are estimated from peak heights in the pooled samples after correction of signal bias using peak heights in heterozygotes. For the PCR primers are tagged to have 5'-ATT or 5'-GTT at their ends for post-labeling of both strands. Samples of DNA (10 ng/ul) are amplified in reaction mixtures containing the buffer (10mM Tris-HCl, pH 8.3 or 9.3, 50mM KCl, 2.0mM MgCl<sub>2</sub>), 0.25μM of each primer, 200μM of each dNTP, and 0.025 units/μl of Taq DNA polymerase premixed with anti-Taq antibody. The two strands of PCR products are differentially labeled with nucleotides modified with R110 and R6G by an exchange reaction of Klenow fragment of DNA polymerase I. The reaction is stopped by adding EDTA, and unincorporated nucleotides are dephosphorylated by adding calf intestinal

alkaline phosphatase. For the SSCP: an aliquot of fluorescently labeled PCR products and TAMRA-labeled internal markers are added to deionized formamide, and denatured. Electrophoresis is performed in a capillary using an ABI Prism 310 Genetic Analyzer. Genescan softwares (P-E Biosystems) are used for data collection and data processing.

5 DNA of individuals (two to eleven) including those who showed different genotypes on SSCP are subjected for direct sequencing using big-dye terminator chemistry, on ABI Prism 310 sequencers. Multiple sequence trace files obtained from ABI Prism 310 are processed and aligned by Phred/Phrap and viewed using Consed viewer. SNPs are identified by PolyPhred software and visual inspection.

10 In yet another method identified as KYUGEN (Method2), individuals with different genotypes are searched by denaturing HPLC (DHPLC) or PLACE-SSCP (Inazuka *et al.*, 1997) and their sequences are determined to identify SNPs. PCR is performed with primers tagged with 5'-ATT or 5'-GTT at their ends for post-labeling of both strands. DHPLC analysis is carried out using the WAVE DNA fragment analysis

15 system (Transgenomic). PCR products are injected into DNASep column, and separated under the conditions determined using WAVEMaker program (Transgenomic). The two strands of PCR products that are differentially labeled with nucleotides modified with R110 and R6G by an exchange reaction of Klenow fragment of DNA polymerase I. The reaction is stopped by adding EDTA, and unincorporated nucleotides are

20 dephosphorylated by adding calf intestinal alkaline phosphatase. SSCP followed by electrophoresis is performed in a capillary using an ABI Prism 310 Genetic Analyzer. Genescan softwares (P-E Biosystems). DNA of individuals including those who showed different genotypes on DHPLC or SSCP are subjected for direct sequencing using big-dye terminator chemistry, on ABI Prism 310 sequencer. Multiple sequence trace files

25 obtained from ABI Prism 310 are processed and aligned by Phred/Phrap and viewed using Consed viewer. SNPs are identified by PolyPhred software and visual inspection. Trace chromatogram data of EST sequences in Unigene are processed with PHRED. To identify likely SNPs, single base mismatches are reported from multiple sequence alignments produced by the programs PHRAP, BRO and POA for each Unigene cluster.

30 BRO corrected possible misreported EST orientations, while POA identified and analyzed non-linear alignment structures indicative of gene mixing/chimeras that might

produce spurious SNPs. Bayesian inference is used to weigh evidence for true polymorphism versus sequencing error, misalignment or ambiguity, misclustering or chimeric EST sequences, assessing data such as raw chromatogram height, sharpness, overlap and spacing; sequencing error rates; context-sensitivity; cDNA library origin, etc.

5 In method identified as MARSHFIELD(Method-B), overlapping human DNA sequences which contained putative insertion/deletion polymorphisms are identified through searches of public databases. PCR primers which flanked each polymorphic site are selected from the consensus sequences. Primers are used to amplify individual or pooled human genomic DNA. Resulting PCR products are resolved on a denaturing  
10 polyacrylamide gel and a PhosphorImager is used to estimate allele frequencies from DNA pools.

## 6. Linkage Disequilibrium

Polymorphisms in linkage disequilibrium with the polymorphism at 3972 of the  
15 *ABCC2* gene locus may also be used with the methods of the present invention. "Linkage disequilibrium" ("LD" as used herein, though also referred to as "LED" in the art) refers to a situation where a particular combination of alleles (*i.e.*, a variant form of a given gene) or polymorphisms at two loci appears more frequently than would be expected by chance. "Significant" as used in respect to linkage disequilibrium, as determined by one  
20 of skill in the art, is contemplated to be a statistical  $p$  or  $\alpha$  value that may be 0.25 or 0.1 and may be 0.1, 0.05, 0.001, 0.00001 or less. The relationship between *ABCC2* haplotypes and the AUC of *ABCC2* substrates may be used to correlate the genotype (*i.e.*, the genetic make up of an organism) to a phenotype (*i.e.*, the physical traits displayed by an organism or cell). "Haplotype" is used according to its plain and  
25 ordinary meaning to one skilled in the art. It refers to a collective genotype of two or more alleles or polymorphisms along one of the homologous chromosomes.

A common haplotype with the 3972 variant includes two promoter variants (-1549A>G and -1019A>G) and a 5'UTR variant (-24C>T). This is found at a frequency of 17.3% in Caucasian, 4.3% in African-Americans, and 10.3% in Asian populations.  
30 The 3972 variant is found alone at a frequency of 5.2% in Caucasians and 4.6% in

African-Americans. A haplotype including the 3972 variant and the -1549 and -1019 promoter variants has a frequency of 9.2% in Caucasians, and 3.7% in African-Americans. Another haplotype with the 3972 variant includes the -1549A>G promoter variant and an intronic variant in intron 13 (+27C>G). This haplotype is found at a frequency of 4.8% in African-Americans.

## V. FORMULATIONS AND DOSAGES

Irinotecan is also known as CPT-11 and it is commercially available as CAMPTOSAR®. CAMPTOSAR® is supplied as a sterile solution in two single-dose sizes: 2-mL vials containing 40 mg irinotecan hydrochloride and 5-mL vials containing 100 mg irinotecan hydrochloride. Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, which is an alkaloid extract from plants including *Camptotheca acuminata*.

CAMPTOSAR® Injection can be administered as a monotherapy, but in some instances is indicated as one agent of a first-line therapy to treat colon or rectal cancer. It has been used in combination with 5-fluorouracil (5-FU) and leucovorin. In some cases, this combination treatment is indicated for patient with recurrent or progressed cancer, after they have undergone a fluorouracil-based therapy.

It can be administered by intravenous infusion. Dosages of CAMPTOSAR® include 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400 or more mg/m<sup>2</sup> on day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 26, 37 or on a weekly regimen, such as every 1, 2, 3, 4 weeks or more for 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 or more consecutive or non-consecutive weeks. It is contemplated that dosages can be adjusted to be less than or more than the concentrations discussed above or less frequently or more frequently than the timing discussed above. It is contemplated treatment cycles may be repeated and that there may be a respite between cycles. One of ordinary skill in the art

is familiar with dosages regimens. In one example of a typical regimen for single-agent CAMPTOSAR® treatment, a patient is provided 125 mg/m<sup>2</sup> IV over 90 minutes on day 1, 8, 15, 22, then a two week rest before the cycle may be resumed. The overall amount of the drug administered to the patient in a single regimen or for the treatment overall may be increased or decreased by about, by at least about, or by at most about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000 mg/m<sup>2</sup> or any ranges derivable therein.

The dosages of other ABCC2 drug substrates (drugs are included in Table 1) that are administered to patients is well known to those of skill in the art. These dosages may be reduced or increased relative to a dosage that would have been administered in the absence of genotyping. It is specifically contemplated that the dosages of any of those drugs may be similarly altered or modified based on genotypic analysis described herein.

## V. KITS

Any of the compositions described herein may be comprised in a kit. In a non-limiting example, reagents for determining the genotype of one or both *ABCC2* genes are included in a kit. The kit may further include individual nucleic acids that can be used to amplify and/or detect particular nucleic acid sequences of the *ABCC2* gene. It may also include one or more buffers, such as a DNA isolation buffers, an amplification buffer or a hybridization buffer. The kit may also contain compounds and reagents to prepare DNA templates and isolate DNA from a sample. The kit may also include various labeling reagents and compounds.

The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquoted. Where there is more than one component in the kit, the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present



invention also will typically include a means for containing the nucleic acids, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow-molded plastic containers into which the desired vials are retained.

5           When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred. However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent  
10           may also be provided in another container means.

A kit will also include instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented.

It is contemplated that such reagents are embodiments of kits of the invention.  
15       Such kits, however, are not limited to the particular items identified above and may include any reagent used directly or indirectly in the detection of polymorphisms in the *ABCC2* gene, particularly the 3972C>T polymorphism. Kits include, in some embodiments, nucleic acids capable of amplifying or of probing for a polymorphism in the *ABCC2* gene.

20

### **EXAMPLES**

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor  
25       to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

30

### **EXAMPLE 1**

#### **CORRELATION OF THE 3972C>T VARIANT OF *ABCC2* WITH IRINOTECAN PHARMACOKINETICS**

- 5            Sixty-four adults (48 Caucasians, 10 African-Americans, 4 Hispanics, and 2 others) with refractory solid tumors took part in the pharmacogenetic study. Genotyping of common variants ( $q > 0.10$  in individuals of African and Caucasian origin) was performed for the following genes (number of variants in parenthesis): CES-2 (n=2), ABCC1 (n=7), ABCC2 (n=6), ABCB1 (n=8), CYP3A4\*1B (n=1), CYP3A5\*3 (n=1), 10    UGT1A9 (n=1), and HNF-1 $\alpha$  (n=1) (Table 2).

| <b>Gene</b>   | <b>Location</b> | <b>Position</b>                                |
|---------------|-----------------|--|
| CES-2         | 16q22.1         | -363C>G, 5'UTR                                 |
| CES-2         | 16q22.1         | 1361G>A, intron 1                              |
| ABCC1         | 16p13.1         | 1062T>C, synonymous                            |
| ABCC1         | 16p13.1         | 8A>G, intron 9                                 |
| ABCC1         | 16p13.1         | -48C>, intron 11                               |
| ABCC1         | 16p13.1         | 1684T>C, synonymous                            |
| ABCC1         | 16p13.1         | -30C>G, intron 18                              |
| ABCC1         | 16p13.1         | 4002G>A, synonymous                            |
| ABCC1         | 16p13.1         | 18A>G, intron 30                               |
| ABCC2         | 10q24           | -1549A>G, promoter                             |
| ABCC2         | 10q24           | -1019A>G, promoter                             |
| ABCC2         | 10q24           | -24C>T, 5'UTR                                  |
| ABCC2         | 10q24           | 1249G>A, nonsynonymous, Val417Ile              |
| ABCC2         | 10q24           | -34T>C, intron 26                              |
| ABCC2         | 10q24           | 3972C>T, synonymous                            |
| ABCB1         | 7q21.1          | -129T>C, 5'UTR                                 |
| ABCB1         | 7q21.1          | -25G>T, intron 4                               |
| ABCB1         | 7q21.1          | -44A>G, intron 9                               |
| ABCB1         | 7q21.1          | 1236C>T, synonymous                            |
| ABCB1         | 7q21.1          | 24C>T, intron 13                               |
| ABCB1         | 7q21.1          | +38A>G, intron 14                              |
| ABCB1         | 7q21.1          | 2677G>T/A, nonsynonymous, Ala893Ser/Thr        |
| ABCB1         | 7q21.1          | 3435C>T, synonymous                            |
| CYP3A4*1B     | 7q21.1          | -392A>G, promoter                              |
| CYP3A5*3      | 7q21.1          | 22893G>A                                       |
| UGT1A9        | 2q37            | -11810T/9T, exon 1, AF297093                   |
| HNF1 $\alpha$ | 12q24.2         | 79A>C, nonsynonymous I27L, exon 1, NM_000545.3 |

Table 2. Genetic variants typed in this study.

Irinotecan, SN-38, SN-38G, and APC AUCs were measured using noncompartmental analysis (WinNonlin) in the 64 patients in the study after a 350 mg/m<sup>2</sup> IV dose of irinotecan. AUC ratios of SN-38/ irinotecan, APC/ irinotecan, and SN-38G/SN-38 were also calculated. After visual inspection of the graphical plots of AUC and ratios stratified by genotype, t test analysis was applied to the data showing the possible presence of an inter-genotype difference in irinotecan pharmacokinetics.

The synonymous 3972C>T (exon 28) in ABCC2 was correlated with irinotecan AUC ( $p=0.02$ ) (FIG. 1), APC AUC ( $p<0.0001$ ) (FIG. 1), and SN-38G AUC ( $p\leq 0.001$ ) (FIG. 2), with the TT patients showing higher AUC values compared to CT and CC patients. Higher values of AUC ratios in the TT patients compared to CT and CC patients were also observed in relation to APC/irinotecan ( $p<0.0001$ ) and SN-38G/SN-38 ( $p\leq 0.001$ ). For SN-38 and SN-38G AUCs, the correlation with 3972C>T was analyzed in patients with 6/6 and 6/7 UGT1A1 genotype ( $n=54$ ) to avoid confounding effects of 7/7 genotypes. No significant correlation was observed between SN-38 AUC and 3972C>T ( $p=0.9$ ) (FIG. 2). The frequency of CC, CT, and TT genotypes in the sample population was 0.44, 0.44, and 0.13, respectively. Other gene variants showed either no or borderline statistical significance in the anova test.

20

\* \* \* \*

All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents that are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and

30

modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

## REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein  
5 by reference.

U.S. Patent 4,582,788

U.S. Patent 4,659,774

U.S. Patent 4,683,194

10 U.S. Patent 4,683,195

U.S. Patent 4,683,202

U.S. Patent 4,683,202

U.S. Patent 4,683,202

U.S. Patent 4,800,159

15 U.S. Patent 4,816,571

U.S. Patent 4,883,750

U.S. Patent 4,946,773

U.S. Patent 4,959,463

U.S. Patent 5,141,813

20 U.S. Patent 5,264,566

U.S. Patent 5,279,721

U.S. Patent 5,428,148

U.S. Patent 5,554,744

U.S. Patent 5,574,146

25 U.S. Patent 5,602,244

U.S. Patent 5,645,897

U.S. Patent 5,705,629

U.S. Patent 5,840,873

U.S. Patent 5,843,640

30 U.S. Patent 5,843,650

U.S. Patent 5,843,651

U.S. Patent 5,843,663  
U.S. Patent 5,846,708  
U.S. Patent 5,846,709  
U.S. Patent 5,846,717  
5 U.S. Patent 5,846,726  
U.S. Patent 5,846,729  
U.S. Patent 5,846,783  
U.S. Patent 5,849,481  
U.S. Patent 5,849,483  
10 U.S. Patent 5,849,486  
U.S. Patent 5,849,487  
U.S. Patent 5,849,497  
U.S. Patent 5,849,546  
U.S. Patent 5,849,547  
15 U.S. Patent 5,851,770  
U.S. Patent 5,851,772  
U.S. Patent 5,853,990  
U.S. Patent 5,853,992  
U.S. Patent 5,853,993  
20 U.S. Patent 5,856,092  
U.S. Patent 5,858,652  
U.S. Patent 5,861,244  
U.S. Patent 5,863,732  
U.S. Patent 5,863,753  
25 U.S. Patent 5,866,331  
U.S. Patent 5,866,337  
U.S. Patent 5,866,366  
U.S. Patent 5,900,481  
U.S. Patent 5,905,024  
30 U.S. Patent 5,910,407  
U.S. Patent 5,912,124

- U.S. Patent 5,912,145  
U.S. Patent 5,912,148  
U.S. Patent 5,916,776  
U.S. Patent 5,916,779  
5 U.S. Patent 5,919,626  
U.S. Patent 5,919,630  
U.S. Patent 5,922,574  
U.S. Patent 5,925,517  
U.S. Patent 5,925,525  
10 U.S. Patent 5,928,862  
U.S. Patent 5,928,869  
U.S. Patent 5,928,870  
U.S. Patent 5,928,905  
U.S. Patent 5,928,906  
15 U.S. Patent 5,929,227  
U.S. Patent 5,932,413  
U.S. Patent 5,932,451  
U.S. Patent 5,935,791  
U.S. Patent 5,935,825  
20 U.S. Patent 5,939,291  
U.S. Patent 5,942,391  
U.S. Patent 5,952,174  
U.S. Patent. 4,656,127  
U.S. Patent 4,682,195  
25  
Araki *et al.*, *Jpn. J. Cancer Res.*, 84:697-702, 1993.  
Ausubel *et al.*, In: *Current Protocols in Molecular Biology*, Green Pub. Assoc., Inc., and  
John Wiley & Sons, Inc., NY, (I):2.10.3, 1989.  
Borst *et al.*, *Biochim. Biophys. Acta*, 1461(2):347-357, 1999  
30 Borst *et al.* *J. Natl. Cancer Inst.*, 92:1295-1302, 2000.  
European Application 329 822

- European Application 320 308
- European Patent 266,032
- European Patent 258,017
- European Patent 50,424
- 5 European Patent 201,184
- European Patent 237,362
- European Patent 84,796
- French Patent 2,650,840
- Froehler *et al.*, *Nucleic Acids Res.*, 14(13):5399-5407, 1986.
- 10 Frohman, In: *PCR Protocols: A Guide To Methods And Applications*, Academic Press, NY, 1990.
- Fuchs *et al.*, *J. Clin. Oncol.*, 21(5):807-814, 1993.
- Great Britain Patent 2 202 328
- Gupta *et al.*, *Cancer Res.*, 54:3723-3725, 1994.
- 15 Gupta *et al.*, *J. Clin. Oncol.*, 15:1502-1510, 1997.
- Halushka *et al.*, *Nat. Genet.*, 22(3):239-247, 1999.
- Inazuka *et al.*, *Genome Res.*, 7(11):1094-1103, 1997.
- Innis *et al.*, *Proc Natl Acad Sci U S A.* 85(24):9436-9440, 1988.
- Iyer *et al.*, *J. Clin. Invest.*, 101:847-854, 1998.
- 20 Johnson *et al.*, *Nat. Genet.*, 29(2):233-237, 2001.
- Kaneda *et al.*, *Cancer Res.*, 50:1715-1720, 1990.
- Ke and Cardon, *Bioinformatics*, 19(2):287-288, 2003.
- Komher, *et al.*, *Nucl. Acids. Res.* 17:7779-7784, 1989.
- Kuppuswamy, *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:1143-1147, 1991.
- 25 Kwok *et al.*, *Proc. Nat. Acad. Sci. USA*, 86:1173, 1989.
- Kwok, *Annu Rev Genomics Hum Genet.*, 2:235-58, 2001.
- Kwok and Chen, *Curr Issues Mol. Biol.*, Apr;5(2):43-60, 2003.
- Kwok *et al.*, *Genomics*, 23(1):138-144, 1994.
- Landegren, *et al.*, *Science*, 241:1077-1080, 1988.
- 30 Maxam, *et al.*, *Proc. Natl. Acad. Sci. USA*, 74:560, 1977.
- Mullis *et al.*, *Cold Spring Harbor Symp. Quant. Biol.* 51:263-273, 1986.



- Negoro *et al.*, *J. Natl. Cancer Inst.*, 83(16):1164-1168, 1991.
- Nickerson *et al.*, *Proc. Natl. Acad. Sci. USA*, 87:8923-8927, 1990.
- Nyren *et al.*, *Anal. Biochem.* 208:171-175, 1993.
- Ohara *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:5673-5677, 1989.
- 5 PCT Application PCT/US87/00880
- PCT Application PCT/US89/01025
- PCT Application WO 88/10315
- PCT Application WO 89/06700
- PCT Application WO91/02087
- 10 PCT Application WO92/15712
- Prezant *et al.*, *Hum. Mutat.* 1:159-164, 1992.
- Rothenberg *et al.*, *J. Clin. Oncol.*, 11(11):2194-21204, 1993.
- Sambrook *et al.*, *In: Molecular Cloning*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001.
- 15 Sanger, *et al.*, *J. Molec. Biol.*, 94:441, 1975.
- Sokolov, *Nucl. Acids Res.* 18:3671, 1990.
- Sparreboom *et al.*, *Drug Resist. Update.*, 3:357-363, 2000.
- Suzuki *et al.*, *Semin. Liver. Dis.* 18:359-376, 1998.
- Suzuki *et al.*, Transporters for bile acids and organic anions, in: G.L. Amidon, W. Sadec  
 20 (eds.), *Membrane Transporters as Drug Targets*, Kluwer Academic/Plenum  
 Publishers, New York, 1999.
- Syvanen *et al.*, *Genomics* 8:684-692, 1990.
- Taillon-Miller *et al.*, *Genome Res*, 8(7):748-754, 1998.
- Ugozzoli *et al.*, *GATA* 9:107-112, 1992.
- 25 Vanhoefer *et al.*, *J. Clin. Oncol.*, 19(5):1501-18, 2001.
- Walker *et al.*, *Proc. Natl. Acad. Sci. USA*, 89:392-396, 1992.

**WHAT IS CLAIMED IS:**

1. A method for predicting the level of ABCC2 activity in a patient comprising:
  - a) determining the sequence at position 3972 in one or both alleles of the  
5 *ABCC2* gene of the patient, wherein a C at position 3972 on one or both  
alleles is indicative of a normal level of ABCC2 activity.
2. The method of claim 2, wherein the sequence at position 3972 is determined for  
both alleles of the *ABCC2* gene.  
10
3. The method of claim 2, wherein a T at position 3972 on both alleles of the  
*ABCC2* gene is indicative of a lower than normal level of ABCC2 activity.
4. The method of claim 1, further comprising obtaining a sample from the patient  
15 and using the sample to determine the sequence at position 3972.
5. The method of claim 4, wherein determining the sequence at position 3972 is  
performed by a hybridization assay.
- 20 6. The method of claim 4, wherein determining the sequence at position 3972 is  
performed by an allele specific amplification assay.
7. The method of claim 4, wherein determining the sequence at position 3972 is  
performed by a sequencing or microsequencing assay.  
25
8. The method of claim 4, wherein the sample comprises buccal cells, mononuclear  
cells, or cancer cells.

9. The method of claim 1, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with the sequence at position 3972.
- 5
10. The method of claim 9, wherein the position in linkage disequilibrium with the sequence at position 3972 is selected from the group consisting of positions -1549, -1019, -24, and +27.
- 10 11. The method of claim 9, wherein the sequence at position 3972 is determined by evaluating the sequence of more than one position in linkage disequilibrium with the sequence at position 3972.
12. The method of claim 1, further comprising administering an ABCC2 substrate to the patient.
- 15
13. The method of claim 1, further comprising analyzing a clearance rate for an ABCC2 substrate.
14. The method of claim 13, wherein the substrate is selected from the group consisting of irinotecan, APC, and SN-38G.
- 20
15. A method for determining dosage of an ABCC2 substrate for a patient comprising:
- 25 a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both

alleles indicates a higher dosage of the substrate than is indicated for a patient with a T at position 3972 in both alleles of the *ABCC2* gene.

5 16. The method of claim 15, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.

17. The method of claim 16, wherein determining the sequence at position 3972 is performed by a hybridization assay.

10 18. The method of claim 16, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.

19. The method of claim 16, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.

15

20. The method of claim 16, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.

20 21. The method of claim 15, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.

25 22. The method of claim 15, further comprising prescribing a dosage of the substrate based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.

23. A method for predicting tumor response to an anticancer agent that is an *ABCC2* substrate in a cancer patient comprising:

- 5           a)       determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles is indicative of a lower probability of an antitumor response to the anticancer agent.

24. The method of claim 23, wherein the sequence at position 3972 is determined for both alleles of the *ABCC2* gene.

10

25. The method of claim 24, wherein a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a higher probability of an antitumor response to the anticancer agent.

15       26. The method of claim 23, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.

27. The method of claim 26, wherein determining the sequence at position 3972 is performed by a hybridization assay.

20

28. The method of claim 26, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.

25       29. The method of claim 26, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.

30. The method of claim 26, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.

5 31. The method of claim 23, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.

32. The method of claim 23, further comprising administering the anticancer agent to the patient.

10

33. The method of claim 32, further comprising administering to the patient a second anticancer agent that is not an *ABCC2* substrate.

15 34. The method of claim 32, further comprising prescribing a dosage of the anticancer agent based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.

35. A method for determining dosage of irinotecan for a patient comprising:  
20 a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 on one or both alleles indicates a higher dosage of irinotecan than is indicated for a patient with a T at position 3972 in both alleles of the *ABCC2* gene.

25 36. The method of claim 35, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.

37. The method of claim 36, wherein determining the sequence at position 3972 is performed by a hybridization assay.
38. The method of claim 36, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.
39. The method of claim 36, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.
40. The method of claim 36, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
41. The method of claim 35, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.
42. The method of claim 35, further comprising prescribing a dosage of irinotecan based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.
43. A method for predicting tumor response to irinotecan in a cancer patient comprising
- a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 in one or both alleles is indicative of a lower probability of an antitumor response to irinotecan.

44. The method of claim 43, wherein the sequence at position 3972 is determined for both alleles of the *ABCC2* gene.
45. The method of claim 44, wherein a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a higher probability of an antitumor response to irinotecan.
46. The method of claim 43, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.
47. The method of claim 46, wherein determining the sequence at position 3972 is performed by a hybridization assay.
48. The method of claim 46, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.
49. The method of claim 46, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.
50. The method of claim 46, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
51. The method of claim 43, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.
52. The method of claim 43, further comprising administering irinotecan to the patient.



53. The method of claim 52, further comprising prescribing a dosage of irinotecan based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.

5

54. A method for predicting a clearance rate for irinotecan in a patient comprising  
a) determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene of the patient, wherein a C at position 3972 in one or both alleles is indicative of a normal clearance rate for irinotecan.

10

55. The method of claim 54, wherein the sequence at position 3972 is determined for both alleles of the *ABCC2* gene.

15 56. The method of claim 55, wherein a T at position 3972 on both alleles of the *ABCC2* gene is indicative of a lower than normal clearance rate for irinotecan.

57. The method of claim 54, further comprising obtaining a sample from the patient and using the sample to determine the sequence at position 3972.

20 58. The method of claim 57, wherein determining the sequence at position 3972 is performed by a hybridization assay.

59. The method of claim 57, wherein determining the sequence at position 3972 is performed by an allele specific amplification assay.

25

60. The method of claim 57, wherein determining the sequence at position 3972 is performed by a sequencing or microsequencing assay.

61. The method of claim 57, wherein the sample comprises buccal cells, mononuclear cells, or cancer cells.
- 5 62. The method of claim 54, wherein the sequence at position 3972 is determined by evaluating the sequence of a position in linkage disequilibrium with a sequence at position 3972.
- 10 63. The method of claim 54, further comprising administering irinotecan to the patient.
64. The method of claim 62, further comprising prescribing a dosage of irinotecan based on determining the sequence at position 3972 in one or both alleles of the *ABCC2* gene.
- 15 65. A kit for predicting a clearance rate for an *ABCC2* substrate in a patient comprising a nucleic acid for determining the sequence at position 3972 in an *ABCC2* gene.
- 20 66. The kit of claim 65, wherein the nucleic acid is a primer for amplifying the sequence at position 3972 in the *ABCC2* gene.
67. The kit of claim 65, wherein the nucleic acid is a specific hybridization probe for detecting the sequence at position 3972 in the *ABCC2* gene.
- 25 68. The kit of claim 67, wherein the specific hybridization probe is comprised in an oligonucleotide array or microarray.

## **ABSTRACT**

The present invention is directed to methods and compositions for determining the presence or absence of polymorphisms within an ABCC2 gene and correlating these polymorphisms with activity levels of ABCC2 and making evaluations regarding the effect on ABCC2 substrates, particularly those substrates that are drugs. In addition, there are methods and compositions of evaluating the risk of an individual for developing toxicity or adverse event(s) to an ABCC2 substrate. In some embodiments, the invention concerns methods and compositions for determining the presence or absence of *ABCC2* 3972C>T variant and predicting or anticipating the level of activity of ABCC2 and determining dosages of an ABCC2 drug substrate, such as irinotecan, in a patient. Such methods and compositions can be used to evaluate whether irinotecan-based therapy, or therapy involving other ABCC2 substrates, may pose toxicity problems if given to a particular patient or predicting their efficacy. Alterations in suggested therapy may ensue based on genotyping results.

# SEQUENCE LISTING

<110> RATAIN, MARK J.  
INNOCENTI, FEDERICO  
KROETZ, DEANNA L.  
UNDEVIA, SAMIR

<120> METHODS AND COMPOSITIONS RELATING TO THE PHARMACOGENETICS  
OF ABCC2 GENE VARIANTS

<130> ARCD:405USP1

<140> UNKNOWN

<141> 2004-03-05

<160> 3

<170> PatentIn Ver. 2.1

<210> 1

<211> 4868

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (38) .. (4675)

<400> 1

```

gcggccgcgt ctttgttcca gacgcagtcc aggaatc atg ctg gag aag ttc tgc 55
                                         Met Leu Glu Lys Phe Cys
                                         1           5

aac tct act ttt tgg aat tcc tca ttc ctg gac agt ccg gag gca gac 103
Asn Ser Thr Phe Trp Asn Ser Ser Phe Leu Asp Ser Pro Glu Ala Asp
          10           15           20

ctg cca ctt tgt ttt gag caa act gtt ctg gtg tgg att ccc ttg ggc 151
Leu Pro Leu Cys Phe Glu Gln Thr Val Leu Val Trp Ile Pro Leu Gly
          25           30           35

ttc cta tgg ctc ctg gcc ccc tgg cag ctt ctc cac gtg tat aaa tcc 199
Phe Leu Trp Leu Leu Ala Pro Trp Gln Leu Leu His Val Tyr Lys Ser
          40           45           50

agg acc aag aga tcc tct acc acc aaa ctc tat ctt gct aag cag gta 247
Arg Thr Lys Arg Ser Ser Thr Thr Lys Leu Tyr Leu Ala Lys Gln Val
          55           60           65           70

ttc gtt ggt ttt ctt ctt att cta gca gcc ata gag ctg gcc ctt gta 295
Phe Val Gly Phe Leu Leu Ile Leu Ala Ala Ile Glu Leu Ala Leu Val
          75           80           85

ctc aca gaa gac tct gga caa gcc aca gtc cct gct gtt cga tat acc 343
Leu Thr Glu Asp Ser Gly Gln Ala Thr Val Pro Ala Val Arg Tyr Thr
          90           95          100

```

|   |      |
|---|------|
| aat cca agc ctc tac cta ggc aca tgg ctc ctg gtt ttg ctg atc caa | 391  |
| Asn Pro Ser Leu Tyr Leu Gly Thr Trp Leu Leu Val Leu Leu Ile Gln |      |
| 105 110 115   |      |
| tac agc aga caa tgg tgt gta cag aaa aac tcc tgg ttc ctg tcc cta | 439  |
| Tyr Ser Arg Gln Trp Cys Val Gln Lys Asn Ser Trp Phe Leu Ser Leu |      |
| 120 125 130   |      |
| ttc tgg att ctc tgc ata ctc tgt ggc act ttc caa ttt cag act ctg | 487  |
| Phe Trp Ile Leu Ser Ile Leu Cys Gly Thr Phe Gln Phe Gln Thr Leu |      |
| 135 140 145 150   |      |
| atc cgg aca ctc tta cag ggt gac aat tct aat cta gcc tac tcc tgc | 535  |
| Ile Arg Thr Leu Leu Gln Gly Asp Asn Ser Asn Leu Ala Tyr Ser Cys |      |
| 155 160 165   |      |
| ctg ttc ttc atc tcc tac gga ttc cag atc ctg atc ctg atc ttt tca | 583  |
| Leu Phe Phe Ile Ser Tyr Gly Phe Gln Ile Leu Ile Leu Ile Phe Ser |      |
| 170 175 180   |      |
| gca ttt tca gaa aat aat gag tca tca aat aat cca tca tcc ata gct | 631  |
| Ala Phe Ser Glu Asn Asn Glu Ser Ser Asn Asn Pro Ser Ser Ile Ala |      |
| 185 190 195   |      |
| tca ttc ctg agt agc att acc tac agc tgg tat gac agc atc att ctg | 679  |
| Ser Phe Leu Ser Ser Ile Thr Tyr Ser Trp Tyr Asp Ser Ile Ile Leu |      |
| 200 205 210   |      |
| aaa ggc tac aag cgt cct ctg aca ctc gag gat gtc tgg gaa gtt gat | 727  |
| Lys Gly Tyr Lys Arg Pro Leu Thr Leu Glu Asp Val Trp Glu Val Asp |      |
| 215 220 225 230   |      |
| gaa gag atg aaa acc aag aca tta gtg agc aag ttt gaa acg cac atg | 775  |
| Glu Glu Met Lys Thr Lys Thr Leu Val Ser Lys Phe Glu Thr His Met |      |
| 235 240 245   |      |
| aag aga gag ctg cag aaa gcc agg cgg gca ctc cag aga cgg cag gag | 823  |
| Lys Arg Glu Leu Gln Lys Ala Arg Arg Ala Leu Gln Arg Arg Gln Glu |      |
| 250 255 260   |      |
| aag agc tcc cag cag aac tct gga gcc agg ctg cct ggc ttg aac aag | 871  |
| Lys Ser Ser Gln Gln Asn Ser Gly Ala Arg Leu Pro Gly Leu Asn Lys |      |
| 265 270 275   |      |
| aat cag agt caa agc caa gat gcc ctt gtc ctg gaa gat gtt gaa aag | 919  |
| Asn Gln Ser Gln Ser Gln Asp Ala Leu Val Leu Glu Asp Val Glu Lys |      |
| 280 285 290   |      |
| aaa aaa aag aag tct ggg acc aaa aaa gat gtt cca aaa tcc tgg ttg | 967  |
| Lys Lys Lys Lys Ser Gly Thr Lys Lys Asp Val Pro Lys Ser Trp Leu |      |
| 295 300 305 310   |      |
| atg aag gct ctg ttc aaa act ttc tac atg gtg ctc ctg aaa tca ttc | 1015 |
| Met Lys Ala Leu Phe Lys Thr Phe Tyr Met Val Leu Leu Lys Ser Phe |      |
| 315 320 325   |      |

|   |      |
|---|------|
| cta ctg aag cta gtg aat gac atc ttc acg ttt gtg agt cct cag ctg | 1063 |
| Leu Leu Lys Leu Val Asn Asp Ile Phe Thr Phe Val Ser Pro Gln Leu |      |
| 330 335 340   |      |
| ctg aaa ttg ctg atc tcc ttt gca agt gac cgt gac aca tat ttg tgg | 1111 |
| Leu Lys Leu Leu Ile Ser Phe Ala Ser Asp Arg Asp Thr Tyr Leu Trp |      |
| 345 350 355   |      |
| att gga tat ctg tgt gca atc ctg tta ttc act gcg gct ctg att cag | 1159 |
| Ile Gly Tyr Leu Cys Ala Ile Leu Leu Phe Thr Ala Ala Leu Ile Gln |      |
| 360 365 370   |      |
| tct ttc tgc ctt cag tgt tat ttc caa ctg tgc ttc aag ctg ggt gta | 1207 |
| Ser Phe Cys Leu Gln Cys Tyr Phe Gln Leu Cys Phe Lys Leu Gly Val |      |
| 375 380 385 390   |      |
| aaa gta cgg aca gct atc atg gct tct gta tat aag aag gca ttg acc | 1255 |
| Lys Val Arg Thr Ala Ile Met Ala Ser Val Tyr Lys Lys Ala Leu Thr |      |
| 395 400 405   |      |
| cta tcc aac ttg gcc agg aag gag tac acc gtt gga gaa aca gtg aac | 1303 |
| Leu Ser Asn Leu Ala Arg Lys Glu Tyr Thr Val Gly Glu Thr Val Asn |      |
| 410 415 420   |      |
| ctg atg tct gtg gat gcc cag aag ctg atg gat gtg acc aac ttc atg | 1351 |
| Leu Met Ser Val Asp Ala Gln Lys Leu Met Asp Val Thr Asn Phe Met |      |
| 425 430 435   |      |
| cac atg ctg tgg tca agt gtt cta cag att gtc tta tct atc ttc ttc | 1399 |
| His Met Leu Trp Ser Ser Val Leu Gln Ile Val Leu Ser Ile Phe Phe |      |
| 440 445 450   |      |
| cta tgg aga gag ttg gga ccc tca gtc tta gca ggt gtt ggg gtg atg | 1447 |
| Leu Trp Arg Glu Leu Gly Pro Ser Val Leu Ala Gly Val Gly Val Met |      |
| 455 460 465 470   |      |
| gtg ctt gta atc cca att aat gcg ata ctg tcc acc aag agt aag acc | 1495 |
| Val Leu Val Ile Pro Ile Asn Ala Ile Leu Ser Thr Lys Ser Lys Thr |      |
| 475 480 485   |      |
| att cag gtc aaa aat atg aag aat aaa gac aaa cgt tta aag atc atg | 1543 |
| Ile Gln Val Lys Asn Met Lys Asn Lys Asp Lys Arg Leu Lys Ile Met |      |
| 490 495 500   |      |
| aat gag att ctt agt gga atc aag atc ctg aaa tat ttt gcc tgg gaa | 1591 |
| Asn Glu Ile Leu Ser Gly Ile Lys Ile Leu Lys Tyr Phe Ala Trp Glu |      |
| 505 510 515   |      |
| cct tca ttc aga gac caa gta caa aac ctg cgg aag aaa gag ctg aag | 1639 |
| Pro Ser Phe Arg Asp Gln Val Gln Asn Leu Arg Lys Lys Glu Leu Lys |      |
| 520 525 530   |      |
| aac ctg ctg gcc ttt agt caa cta cag tgt gta gta ata ttc gtc ttc | 1687 |
| Asn Leu Leu Ala Phe Ser Gln Leu Gln Cys Val Val Ile Phe Val Phe |      |
| 535 540 545 550   |      |
| cag tta act cca gtc ctg gta tct gtg gtc aca ttt tct gtt tat gtc | 1735 |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |  |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|--|
| Gln | Leu | Thr | Pro | Val | Leu | Val | Ser | Val | Val | Thr | Phe | Ser | Val | Tyr | Val |      |  |
|     |     |     |     | 555 |     |     |     |     | 560 |     |     |     |     | 565 |     |      |  |
| ctg | gtg | gat | agc | aac | aat | att | ttg | gat | gca | caa | aag | gcc | ttc | acc | tcc | 1783 |  |
| Leu | Val | Asp | Ser | Asn | Asn | Ile | Leu | Asp | Ala | Gln | Lys | Ala | Phe | Thr | Ser |      |  |
|     |     |     | 570 |     |     |     |     | 575 |     |     |     | 580 |     |     |     |      |  |
| att | acc | ctc | ttc | aat | atc | ctg | cgc | ttt | ccc | ctg | agc | atg | ctt | ccc | atg | 1831 |  |
| Ile | Thr | Leu | Phe | Asn | Ile | Leu | Arg | Phe | Pro | Leu | Ser | Met | Leu | Pro | Met |      |  |
|     |     | 585 |     |     |     |     | 590 |     |     |     |     | 595 |     |     |     |      |  |
| atg | atc | tcc | tcc | atg | ctc | cag | gcc | agt | gtt | tcc | aca | gag | cgg | cta | gag | 1879 |  |
| Met | Ile | Ser | Ser | Met | Leu | Gln | Ala | Ser | Val | Ser | Thr | Glu | Arg | Leu | Glu |      |  |
|     | 600 |     |     |     |     | 605 |     |     |     |     | 610 |     |     |     |     |      |  |
| aag | tac | ttg | gga | ggg | gat | gac | ttg | gac | aca | tct | gcc | att | cga | cat | gac | 1927 |  |
| Lys | Tyr | Leu | Gly | Gly | Asp | Asp | Leu | Asp | Thr | Ser | Ala | Ile | Arg | His | Asp |      |  |
| 615 |     |     |     | 620 |     |     |     |     | 625 |     |     |     |     | 630 |     |      |  |
| tgc | aat | ttt | gac | aaa | gcc | atg | cag | ttt | tct | gag | gcc | tcc | ttt | acc | tgg | 1975 |  |
| Cys | Asn | Phe | Asp | Lys | Ala | Met | Gln | Phe | Ser | Glu | Ala | Ser | Phe | Thr | Trp |      |  |
|     |     |     | 635 |     |     |     |     | 640 |     |     |     |     |     | 645 |     |      |  |
| gaa | cat | gat | tcg | gaa | gcc | aca | gtc | cga | gat | gtg | aac | ctg | gac | att | atg | 2023 |  |
| Glu | His | Asp | Ser | Glu | Ala | Thr | Val | Arg | Asp | Val | Asn | Leu | Asp | Ile | Met |      |  |
|     |     |     | 650 |     |     |     |     | 655 |     |     |     | 660 |     |     |     |      |  |
| gca | ggc | caa | ctt | gtg | gct | gtg | ata | ggc | cct | gtc | ggc | tct | ggg | aaa | tcc | 2071 |  |
| Ala | Gly | Gln | Leu | Val | Ala | Val | Ile | Gly | Pro | Val | Gly | Ser | Gly | Lys | Ser |      |  |
|     | 665 |     |     |     |     | 670 |     |     |     |     |     | 675 |     |     |     |      |  |
| tcc | ttg | ata | tca | gcc | atg | ctg | gga | gaa | atg | gaa | aat | gtc | cac | ggg | cac | 2119 |  |
| Ser | Leu | Ile | Ser | Ala | Met | Leu | Gly | Glu | Met | Glu | Asn | Val | His | Gly | His |      |  |
|     | 680 |     |     |     |     | 685 |     |     |     |     | 690 |     |     |     |     |      |  |
| atc | acc | atc | aag | ggc | acc | act | gcc | tat | gtc | cca | cag | cag | tcc | tgg | att | 2167 |  |
| Ile | Thr | Ile | Lys | Gly | Thr | Thr | Ala | Tyr | Val | Pro | Gln | Gln | Ser | Trp | Ile |      |  |
| 695 |     |     |     | 700 |     |     |     |     | 705 |     |     |     |     | 710 |     |      |  |
| cag | aat | ggc | acc | ata | aag | gac | aac | atc | ctt | ttt | gga | aca | gag | ttt | aat | 2215 |  |
| Gln | Asn | Gly | Thr | Ile | Lys | Asp | Asn | Ile | Leu | Phe | Gly | Thr | Glu | Phe | Asn |      |  |
|     |     |     | 715 |     |     |     |     | 720 |     |     |     |     | 725 |     |     |      |  |
| gaa | aag | agg | tac | cag | caa | gta | ctg | gag | gcc | tgt | gct | ctc | ctc | cca | gac | 2263 |  |
| Glu | Lys | Arg | Tyr | Gln | Gln | Val | Leu | Glu | Ala | Cys | Ala | Leu | Leu | Pro | Asp |      |  |
|     |     |     | 730 |     |     |     |     | 735 |     |     |     | 740 |     |     |     |      |  |
| ttg | gaa | atg | ctg | cct | gga | gga | gat | ttg | gct | gag | att | gga | gag | aag | ggc | 2311 |  |
| Leu | Glu | Met | Leu | Pro | Gly | Gly | Asp | Leu | Ala | Glu | Ile | Gly | Glu | Lys | Gly |      |  |
|     | 745 |     |     |     |     | 750 |     |     |     |     |     | 755 |     |     |     |      |  |
| ata | aat | ctt | agt | ggg | ggc | cag | aag | cag | cgg | atc | agc | ctg | gcc | aga | gct | 2359 |  |
| Ile | Asn | Leu | Ser | Gly | Gly | Gln | Lys | Gln | Arg | Ile | Ser | Leu | Ala | Arg | Ala |      |  |
|     | 760 |     |     |     |     | 765 |     |     |     |     | 770 |     |     |     |     |      |  |
| acc | tac | caa | aat | tta | gac | atc | tat | ctt | cta | gat | gac | ccc | ctg | tct | gca | 2407 |  |
| Thr | Tyr | Gln | Asn | Leu | Asp | Ile | Tyr | Leu | Leu | Asp | Asp | Pro | Leu | Ser | Ala |      |  |

| 775   | 780  | 785  | 790  |      |
|---|------|------|------|------|
| gtg gat gct cat gta gga aaa cat att ttt aat aag gtc ttg ggc ccc |      |      |      | 2455 |
| Val Asp Ala His Val Gly Lys His Ile Phe Asn Lys Val Leu Gly Pro |      |      |      |      |
|   | 795  | 800  | 805  |      |
| aat ggc ctg ttg aaa ggc aag act cga ctc ttg gtt aca cat agc atg |      |      |      | 2503 |
| Asn Gly Leu Leu Lys Gly Lys Thr Arg Leu Leu Val Thr His Ser Met |      |      |      |      |
|   | 810  | 815  | 820  |      |
| cac ttt ctt cct caa gtg gat gag att gta gtt ctg ggg aat gga aca |      |      |      | 2551 |
| His Phe Leu Pro Gln Val Asp Glu Ile Val Val Leu Gly Asn Gly Thr |      |      |      |      |
|   | 825  | 830  | 835  |      |
| att gta gag aaa gga tcc tac agt gct ctc ctg gcc aaa aaa gga gag |      |      |      | 2599 |
| Ile Val Glu Lys Gly Ser Tyr Ser Ala Leu Leu Ala Lys Lys Gly Glu |      |      |      |      |
|   | 840  | 845  | 850  |      |
| ttt gct aag aat ctg aag aca ttt cta aga cat aca ggc cct gaa gag |      |      |      | 2647 |
| Phe Ala Lys Asn Leu Lys Thr Phe Leu Arg His Thr Gly Pro Glu Glu |      |      |      |      |
|   | 855  | 860  | 865  | 870  |
| gaa gcc aca gtc cat gat ggc agt gaa gaa gaa gac gat gac tat ggg |      |      |      | 2695 |
| Glu Ala Thr Val His Asp Gly Ser Glu Glu Glu Asp Asp Asp Tyr Gly |      |      |      |      |
|   | 875  | 880  | 885  |      |
| ctg ata tcc agt gtg gaa gag atc ccc gaa gat gca gcc tcc ata acc |      |      |      | 2743 |
| Leu Ile Ser Ser Val Glu Glu Ile Pro Glu Asp Ala Ala Ser Ile Thr |      |      |      |      |
|   | 890  | 895  | 900  |      |
| atg aga aga gag aac agc ttt cgt cga aca ctt agc cgc agt tct agg |      |      |      | 2791 |
| Met Arg Arg Glu Asn Ser Phe Arg Arg Thr Leu Ser Arg Ser Ser Arg |      |      |      |      |
|   | 905  | 910  | 915  |      |
| tcc aat ggc agg cat ctg aag tcc ctg aga aac tcc ttg aaa act cgg |      |      |      | 2839 |
| Ser Asn Gly Arg His Leu Lys Ser Leu Arg Asn Ser Leu Lys Thr Arg |      |      |      |      |
|   | 920  | 925  | 930  |      |
| aat gtg aat agc ctg aag gaa gac gaa gaa cta gtg aaa gga caa aaa |      |      |      | 2887 |
| Asn Val Asn Ser Leu Lys Glu Asp Glu Glu Leu Val Lys Gly Gln Lys |      |      |      |      |
|   | 935  | 940  | 945  | 950  |
| cta att aag aag gaa ttc ata gaa act gga aag gtg aag ttc tcc atc |      |      |      | 2935 |
| Leu Ile Lys Lys Glu Phe Ile Glu Thr Gly Lys Val Lys Phe Ser Ile |      |      |      |      |
|   | 955  | 960  | 965  |      |
| tac ctg gag tac cta caa gca ata gga ttg ttt tcg ata ttc ttc atc |      |      |      | 2983 |
| Tyr Leu Glu Tyr Leu Gln Ala Ile Gly Leu Phe Ser Ile Phe Phe Ile |      |      |      |      |
|   | 970  | 975  | 980  |      |
| atc ctt gcg ttt gtg atg aat tct gtg gct ttt att gga tcc aac ctc |      |      |      | 3031 |
| Ile Leu Ala Phe Val Met Asn Ser Val Ala Phe Ile Gly Ser Asn Leu |      |      |      |      |
|   | 985  | 990  | 995  |      |
| tgg ctc agt gct tgg acc agt gac tct aaa atc ttc aat agc acc gac |      |      |      | 3079 |
| Trp Leu Ser Ala Trp Thr Ser Asp Ser Lys Ile Phe Asn Ser Thr Asp |      |      |      |      |
|   | 1000 | 1005 | 1010 |      |





|   |      |
|---|------|
| ggc ttt gtt ctg tcc aat gca ctc aat atc aca caa acc ctg aac tgg | 3799 |
| Gly Phe Val Leu Ser Asn Ala Leu Asn Ile Thr Gln Thr Leu Asn Trp |      |
| 1240 1245 1250  |      |
| ctg gtg agg atg aca tca gaa ata gag acc aac att gtg gct gtt gag | 3847 |
| Leu Val Arg Met Thr Ser Glu Ile Glu Thr Asn Ile Val Ala Val Glu |      |
| 1255 1260 1265 1270   |      |
| cga ata act gag tac aca aaa gtg gaa aat gag gca ccc tgg gtg act | 3895 |
| Arg Ile Thr Glu Tyr Thr Lys Val Glu Asn Glu Ala Pro Trp Val Thr |      |
| 1275 1280 1285  |      |
| gat aag agg cct ccg cca gat tgg ccc agc aaa ggc aag atc cag ttt | 3943 |
| Asp Lys Arg Pro Pro Pro Asp Trp Pro Ser Lys Gly Lys Ile Gln Phe |      |
| 1290 1295 1300  |      |
| aac aac tac caa gtg cgg tac cga cct gag ctg gat ctg gtc ctc aga | 3991 |
| Asn Asn Tyr Gln Val Arg Tyr Arg Pro Glu Leu Asp Leu Val Leu Arg |      |
| 1305 1310 1315  |      |
| ggg atc act tgt gac atc ggt agc atg gag aag att ggt gtg gtg ggc | 4039 |
| Gly Ile Thr Cys Asp Ile Gly Ser Met Glu Lys Ile Gly Val Val Gly |      |
| 1320 1325 1330  |      |
| agg aca gga gct gga aag tca tcc ctc aca aac tgc ctc ttc aga atc | 4087 |
| Arg Thr Gly Ala Gly Lys Ser Ser Leu Thr Asn Cys Leu Phe Arg Ile |      |
| 1335 1340 1345 1350   |      |
| tta gag gct gcc ggt ggt cag att atc att gat gga gta gat att gct | 4135 |
| Leu Glu Ala Ala Gly Gly Gln Ile Ile Ile Asp Gly Val Asp Ile Ala |      |
| 1355 1360 1365  |      |
| tcc att ggg ctc cac gac ctc cga gag aag ctg acc atc atc ccc cag | 4183 |
| Ser Ile Gly Leu His Asp Leu Arg Glu Lys Leu Thr Ile Ile Pro Gln |      |
| 1370 1375 1380  |      |
| gac ccc atc ctg ttc tct gga agc ctg agg atg aat ctc gac cct ttc | 4231 |
| Asp Pro Ile Leu Phe Ser Gly Ser Leu Arg Met Asn Leu Asp Pro Phe |      |
| 1385 1390 1395  |      |
| aac aac tac tca gat gag gag att tgg aag gcc ttg gag ctg gct cac | 4279 |
| Asn Asn Tyr Ser Asp Glu Glu Ile Trp Lys Ala Leu Glu Leu Ala His |      |
| 1400 1405 1410  |      |
| ctc aag tct ttt gtg gcc agc ctg caa ctt ggg tta tcc cac gaa gtg | 4327 |
| Leu Lys Ser Phe Val Ala Ser Leu Gln Leu Gly Leu Ser His Glu Val |      |
| 1415 1420 1425 1430   |      |
| aca gag gct ggt ggc aac ctg agc ata ggc cag agg cag ctg ctg tgc | 4375 |
| Thr Glu Ala Gly Gly Asn Leu Ser Ile Gly Gln Arg Gln Leu Leu Cys |      |
| 1435 1440 1445  |      |
| ctg ggc agg gct ctg ctt cgg aaa tcc aag atc ctg gtc ctg gat gag | 4423 |
| Leu Gly Arg Ala Leu Leu Arg Lys Ser Lys Ile Leu Val Leu Asp Glu |      |
| 1450 1455 1460  |      |
| gcc act gct gcg gtg gat cta gag aca gac aac ctc att cag acg acc | 4471 |

Ala Thr Ala Ala Val Asp Leu Glu Thr Asp Asn Leu Ile Gln Thr Thr  
1465 1470 1475

atc caa aac gag ttc gcc cac tgc aca gtg atc acc atc gcc cac agg 4519  
Ile Gln Asn Glu Phe Ala His Cys Thr Val Ile Thr Ile Ala His Arg  
1480 1485 1490

ctg cac acc atc atg gac agt gac aag gta atg gtc cta gac aac ggg 4567  
Leu His Thr Ile Met Asp Ser Asp Lys Val Met Val Leu Asp Asn Gly  
1495 1500 1505 1510

aag att ata gag tgc ggc agc cct gaa gaa ctg cta caa atc cct gga 4615  
Lys Ile Ile Glu Cys Gly Ser Pro Glu Glu Leu Leu Gln Ile Pro Gly  
1515 1520 1525

ccc ttt tac ttt atg gct aag gaa gct ggc att gag aat gtg aac agc 4663  
Pro Phe Tyr Phe Met Ala Lys Glu Ala Gly Ile Glu Asn Val Asn Ser  
1530 1535 1540

aca aaa ttc tag cagaaggccc catgggtag aaaaggacta taagaataat 4715  
Thr Lys Phe  
1545

ttcttatttta attttatttt ttataaaata cagaatacat acaaaagtgt gtataaaatg 4775

tacgtttttaa aaaaggataa gtgaacaccc atgaacctac taccaggtt aagaaaataa 4835

atgtcaccag gtacttgaga aaccctcga ttg 4868

<210> 2  
<211> 1545  
<212> PRT  
<213> Homo sapiens

<400> 2  
Met Leu Glu Lys Phe Cys Asn Ser Thr Phe Trp Asn Ser Ser Phe Leu  
1 5 10 15  
Asp Ser Pro Glu Ala Asp Leu Pro Leu Cys Phe Glu Gln Thr Val Leu  
20 25 30  
Val Trp Ile Pro Leu Gly Phe Leu Trp Leu Leu Ala Pro Trp Gln Leu  
35 40 45  
Leu His Val Tyr Lys Ser Arg Thr Lys Arg Ser Ser Thr Thr Lys Leu  
50 55 60  
Tyr Leu Ala Lys Gln Val Phe Val Gly Phe Leu Leu Ile Leu Ala Ala  
65 70 75 80  
Ile Glu Leu Ala Leu Val Leu Thr Glu Asp Ser Gly Gln Ala Thr Val  
85 90 95  
Pro Ala Val Arg Tyr Thr Asn Pro Ser Leu Tyr Leu Gly Thr Trp Leu  
100 105 110  
Leu Val Leu Leu Ile Gln Tyr Ser Arg Gln Trp Cys Val Gln Lys Asn  
115 120 125  
Ser Trp Phe Leu Ser Leu Phe Trp Ile Leu Ser Ile Leu Cys Gly Thr  
130 135 140  
Phe Gln Phe Gln Thr Leu Ile Arg Thr Leu Leu Gln Gly Asp Asn Ser  
145 150 155 160  
Asn Leu Ala Tyr Ser Cys Leu Phe Phe Ile Ser Tyr Gly Phe Gln Ile

25391509.1

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
|     |     |     |     | 165 |     |     |     | 170 |     |     |     | 175 |     |     |     |
| Leu | Ile | Leu | Ile | Phe | Ser | Ala | Phe | Ser | Glu | Asn | Asn | Glu | Ser | Ser | Asn |
|     |     |     | 180 |     |     |     |     | 185 |     |     |     | 190 |     |     |     |
| Asn | Pro | Ser | Ser | Ile | Ala | Ser | Phe | Leu | Ser | Ser | Ile | Thr | Tyr | Ser | Trp |
|     |     | 195 |     |     |     |     | 200 |     |     |     |     | 205 |     |     |     |
| Tyr | Asp | Ser | Ile | Ile | Leu | Lys | Gly | Tyr | Lys | Arg | Pro | Leu | Thr | Leu | Glu |
|     | 210 |     |     |     |     | 215 |     |     |     |     | 220 |     |     |     |     |
| Asp | Val | Trp | Glu | Val | Asp | Glu | Glu | Met | Lys | Thr | Lys | Thr | Leu | Val | Ser |
|     | 225 |     |     |     | 230 |     |     |     |     | 235 |     |     |     |     | 240 |
| Lys | Phe | Glu | Thr | His | Met | Lys | Arg | Glu | Leu | Gln | Lys | Ala | Arg | Arg | Ala |
|     |     |     | 245 |     |     |     |     | 250 |     |     |     |     |     | 255 |     |
| Leu | Gln | Arg | Arg | Gln | Glu | Lys | Ser | Ser | Gln | Gln | Asn | Ser | Gly | Ala | Arg |
|     |     | 260 |     |     |     |     |     | 265 |     |     |     |     | 270 |     |     |
| Leu | Pro | Gly | Leu | Asn | Lys | Asn | Gln | Ser | Gln | Ser | Gln | Asp | Ala | Leu | Val |
|     | 275 |     |     |     |     |     | 280 |     |     |     |     | 285 |     |     |     |
| Leu | Glu | Asp | Val | Glu | Lys | Lys | Lys | Lys | Lys | Ser | Gly | Thr | Lys | Lys | Asp |
|     | 290 |     |     |     |     | 295 |     |     |     |     | 300 |     |     |     |     |
| Val | Pro | Lys | Ser | Trp | Leu | Met | Lys | Ala | Leu | Phe | Lys | Thr | Phe | Tyr | Met |
|     | 305 |     |     |     | 310 |     |     |     |     | 315 |     |     |     |     | 320 |
| Val | Leu | Leu | Lys | Ser | Phe | Leu | Leu | Lys | Leu | Val | Asn | Asp | Ile | Phe | Thr |
|     |     |     | 325 |     |     |     |     | 330 |     |     |     |     |     | 335 |     |
| Phe | Val | Ser | Pro | Gln | Leu | Leu | Lys | Leu | Leu | Ile | Ser | Phe | Ala | Ser | Asp |
|     |     | 340 |     |     |     |     |     | 345 |     |     |     |     | 350 |     |     |
| Arg | Asp | Thr | Tyr | Leu | Trp | Ile | Gly | Tyr | Leu | Cys | Ala | Ile | Leu | Leu | Phe |
|     | 355 |     |     |     |     |     | 360 |     |     |     |     | 365 |     |     |     |
| Thr | Ala | Ala | Leu | Ile | Gln | Ser | Phe | Cys | Leu | Gln | Cys | Tyr | Phe | Gln | Leu |
|     | 370 |     |     |     | 375 |     |     |     |     |     | 380 |     |     |     |     |
| Cys | Phe | Lys | Leu | Gly | Val | Lys | Val | Arg | Thr | Ala | Ile | Met | Ala | Ser | Val |
|     | 385 |     |     |     | 390 |     |     |     |     | 395 |     |     |     |     | 400 |
| Tyr | Lys | Lys | Ala | Leu | Thr | Leu | Ser | Asn | Leu | Ala | Arg | Lys | Glu | Tyr | Thr |
|     |     |     | 405 |     |     |     |     | 410 |     |     |     |     |     | 415 |     |
| Val | Gly | Glu | Thr | Val | Asn | Leu | Met | Ser | Val | Asp | Ala | Gln | Lys | Leu | Met |
|     |     | 420 |     |     |     |     |     | 425 |     |     |     |     | 430 |     |     |
| Asp | Val | Thr | Asn | Phe | Met | His | Met | Leu | Trp | Ser | Ser | Val | Leu | Gln | Ile |
|     | 435 |     |     |     |     |     | 440 |     |     |     |     | 445 |     |     |     |
| Val | Leu | Ser | Ile | Phe | Phe | Leu | Trp | Arg | Glu | Leu | Gly | Pro | Ser | Val | Leu |
|     | 450 |     |     |     |     | 455 |     |     |     |     | 460 |     |     |     |     |
| Ala | Gly | Val | Gly | Val | Met | Val | Leu | Val | Ile | Pro | Ile | Asn | Ala | Ile | Leu |
|     | 465 |     |     |     | 470 |     |     |     |     | 475 |     |     |     |     | 480 |
| Ser | Thr | Lys | Ser | Lys | Thr | Ile | Gln | Val | Lys | Asn | Met | Lys | Asn | Lys | Asp |
|     |     |     | 485 |     |     |     |     | 490 |     |     |     |     |     | 495 |     |
| Lys | Arg | Leu | Lys | Ile | Met | Asn | Glu | Ile | Leu | Ser | Gly | Ile | Lys | Ile | Leu |
|     |     | 500 |     |     |     |     |     | 505 |     |     |     |     | 510 |     |     |
| Lys | Tyr | Phe | Ala | Trp | Glu | Pro | Ser | Phe | Arg | Asp | Gln | Val | Gln | Asn | Leu |
|     | 515 |     |     |     |     |     | 520 |     |     |     |     | 525 |     |     |     |
| Arg | Lys | Lys | Glu | Leu | Lys | Asn | Leu | Leu | Ala | Phe | Ser | Gln | Leu | Gln | Cys |
|     | 530 |     |     |     |     | 535 |     |     |     |     | 540 |     |     |     |     |
| Val | Val | Ile | Phe | Val | Phe | Gln | Leu | Thr | Pro | Val | Leu | Val | Ser | Val | Val |
|     | 545 |     |     |     | 550 |     |     |     |     | 555 |     |     |     |     | 560 |
| Thr | Phe | Ser | Val | Tyr | Val | Leu | Val | Asp | Ser | Asn | Asn | Ile | Leu | Asp | Ala |
|     |     |     | 565 |     |     |     |     | 570 |     |     |     |     | 575 |     |     |
| Gln | Lys | Ala | Phe | Thr | Ser | Ile | Thr | Leu | Phe | Asn | Ile | Leu | Arg | Phe | Pro |
|     |     | 580 |     |     |     |     | 585 |     |     |     |     | 590 |     |     |     |
| Leu | Ser | Met | Leu | Pro | Met | Met | Ile | Ser | Ser | Met | Leu | Gln | Ala | Ser | Val |
|     | 595 |     |     |     |     | 600 |     |     |     |     |     | 605 |     |     |     |
| Ser | Thr | Glu | Arg | Leu | Glu | Lys | Tyr | Leu | Gly | Gly | Asp | Asp | Leu | Asp | Thr |
|     | 610 |     |     |     |     | 615 |     |     |     |     | 620 |     |     |     |     |



|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |      |      |      |      |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|
| Ser | Ala | Ile | Arg | His | Asp | Cys | Asn | Phe | Asp | Lys | Ala | Met | Gln | Phe | Ser | 625  | 630  | 635  | 640  |
| Glu | Ala | Ser | Phe | Thr | Trp | Glu | His | Asp | Ser | Glu | Ala | Thr | Val | Arg | Asp | 645  | 650  | 655  |      |
| Val | Asn | Leu | Asp | Ile | Met | Ala | Gly | Gln | Leu | Val | Ala | Val | Ile | Gly | Pro | 660  | 665  | 670  |      |
| Val | Gly | Ser | Gly | Lys | Ser | Ser | Leu | Ile | Ser | Ala | Met | Leu | Gly | Glu | Met | 675  | 680  | 685  |      |
| Glu | Asn | Val | His | Gly | His | Ile | Thr | Ile | Lys | Gly | Thr | Thr | Ala | Tyr | Val | 690  | 695  | 700  |      |
| Pro | Gln | Gln | Ser | Trp | Ile | Gln | Asn | Gly | Thr | Ile | Lys | Asp | Asn | Ile | Leu | 705  | 710  | 715  | 720  |
| Phe | Gly | Thr | Glu | Phe | Asn | Glu | Lys | Arg | Tyr | Gln | Gln | Val | Leu | Glu | Ala | 725  | 730  | 735  |      |
| Cys | Ala | Leu | Leu | Pro | Asp | Leu | Glu | Met | Leu | Pro | Gly | Gly | Asp | Leu | Ala | 740  | 745  | 750  |      |
| Glu | Ile | Gly | Glu | Lys | Gly | Ile | Asn | Leu | Ser | Gly | Gly | Gln | Lys | Gln | Arg | 755  | 760  | 765  |      |
| Ile | Ser | Leu | Ala | Arg | Ala | Thr | Tyr | Gln | Asn | Leu | Asp | Ile | Tyr | Leu | Leu | 770  | 775  | 780  |      |
| Asp | Asp | Pro | Leu | Ser | Ala | Val | Asp | Ala | His | Val | Gly | Lys | His | Ile | Phe | 785  | 790  | 795  | 800  |
| Asn | Lys | Val | Leu | Gly | Pro | Asn | Gly | Leu | Leu | Lys | Gly | Lys | Thr | Arg | Leu | 805  | 810  | 815  |      |
| Leu | Val | Thr | His | Ser | Met | His | Phe | Leu | Pro | Gln | Val | Asp | Glu | Ile | Val | 820  | 825  | 830  |      |
| Val | Leu | Gly | Asn | Gly | Thr | Ile | Val | Glu | Lys | Gly | Ser | Tyr | Ser | Ala | Leu | 835  | 840  | 845  |      |
| Leu | Ala | Lys | Lys | Gly | Glu | Phe | Ala | Lys | Asn | Leu | Lys | Thr | Phe | Leu | Arg | 850  | 855  | 860  |      |
| His | Thr | Gly | Pro | Glu | Glu | Glu | Ala | Thr | Val | His | Asp | Gly | Ser | Glu | Glu | 865  | 870  | 875  | 880  |
| Glu | Asp | Asp | Asp | Tyr | Gly | Leu | Ile | Ser | Ser | Val | Glu | Glu | Ile | Pro | Glu | 885  | 890  | 895  |      |
| Asp | Ala | Ala | Ser | Ile | Thr | Met | Arg | Arg | Glu | Asn | Ser | Phe | Arg | Arg | Thr | 900  | 905  | 910  |      |
| Leu | Ser | Arg | Ser | Ser | Arg | Ser | Asn | Gly | Arg | His | Leu | Lys | Ser | Leu | Arg | 915  | 920  | 925  |      |
| Asn | Ser | Leu | Lys | Thr | Arg | Asn | Val | Asn | Ser | Leu | Lys | Glu | Asp | Glu | Glu | 930  | 935  | 940  |      |
| Leu | Val | Lys | Gly | Gln | Lys | Leu | Ile | Lys | Lys | Glu | Phe | Ile | Glu | Thr | Gly | 945  | 950  | 955  | 960  |
| Lys | Val | Lys | Phe | Ser | Ile | Tyr | Leu | Glu | Tyr | Leu | Gln | Ala | Ile | Gly | Leu | 965  | 970  | 975  |      |
| Phe | Ser | Ile | Phe | Phe | Ile | Ile | Leu | Ala | Phe | Val | Met | Asn | Ser | Val | Ala | 980  | 985  | 990  |      |
| Phe | Ile | Gly | Ser | Asn | Leu | Trp | Leu | Ser | Ala | Trp | Thr | Ser | Asp | Ser | Lys | 995  | 1000 | 1005 |      |
| Ile | Phe | Asn | Ser | Thr | Asp | Tyr | Pro | Ala | Ser | Gln | Arg | Asp | Met | Arg | Val | 1010 | 1015 | 1020 |      |
| Gly | Val | Tyr | Gly | Ala | Leu | Gly | Leu | Ala | Gln | Gly | Ile | Phe | Val | Phe | Ile | 1025 | 1030 | 1035 | 1040 |
| Ala | His | Phe | Trp | Ser | Ala | Phe | Gly | Phe | Val | His | Ala | Ser | Asn | Ile | Leu | 1045 | 1050 | 1055 |      |
| His | Lys | Gln | Leu | Leu | Asn | Asn | Ile | Leu | Arg | Ala | Pro | Met | Arg | Phe | Phe | 1060 | 1065 | 1070 |      |
| Asp | Thr | Thr | Pro | Thr | Gly | Arg | Ile | Val | Asn | Arg | Phe | Ala | Gly | Asp | Ile |      |      |      |      |

|   |      |      |
|---|------|------|
| 1075  | 1080 | 1085 |
| Ser Thr Val Asp Asp Thr Leu Pro Gln Ser Leu Arg Ser Trp Ile Thr |      |      |
| 1090  | 1095 | 1100 |
| Cys Phe Leu Gly Ile Ile Ser Thr Leu Val Met Ile Cys Met Ala Thr |      |      |
| 1105  | 1110 | 1115 |
| Pro Val Phe Thr Ile Ile Val Ile Pro Leu Gly Ile Ile Tyr Val Ser |      |      |
| 1125  | 1130 | 1135 |
| Val Gln Met Phe Tyr Val Ser Thr Ser Arg Gln Leu Arg Arg Leu Asp |      |      |
| 1140  | 1145 | 1150 |
| Ser Val Thr Arg Ser Pro Ile Tyr Ser His Phe Ser Glu Thr Val Ser |      |      |
| 1155  | 1160 | 1165 |
| Gly Leu Pro Val Ile Arg Ala Phe Glu His Gln Gln Arg Phe Leu Lys |      |      |
| 1170  | 1175 | 1180 |
| His Asn Glu Val Arg Ile Asp Thr Asn Gln Lys Cys Val Phe Ser Trp |      |      |
| 1185  | 1190 | 1195 |
| Ile Thr Ser Asn Arg Trp Leu Ala Ile Arg Leu Glu Leu Val Gly Asn |      |      |
| 1205  | 1210 | 1215 |
| Leu Thr Val Phe Phe Ser Ala Leu Met Met Val Ile Tyr Arg Asp Thr |      |      |
| 1220  | 1225 | 1230 |
| Leu Ser Gly Asp Thr Val Gly Phe Val Leu Ser Asn Ala Leu Asn Ile |      |      |
| 1235  | 1240 | 1245 |
| Thr Gln Thr Leu Asn Trp Leu Val Arg Met Thr Ser Glu Ile Glu Thr |      |      |
| 1250  | 1255 | 1260 |
| Asn Ile Val Ala Val Glu Arg Ile Thr Glu Tyr Thr Lys Val Glu Asn |      |      |
| 1265  | 1270 | 1275 |
| Glu Ala Pro Trp Val Thr Asp Lys Arg Pro Pro Pro Asp Trp Pro Ser |      |      |
| 1285  | 1290 | 1295 |
| Lys Gly Lys Ile Gln Phe Asn Asn Tyr Gln Val Arg Tyr Arg Pro Glu |      |      |
| 1300  | 1305 | 1310 |
| Leu Asp Leu Val Leu Arg Gly Ile Thr Cys Asp Ile Gly Ser Met Glu |      |      |
| 1315  | 1320 | 1325 |
| Lys Ile Gly Val Val Gly Arg Thr Gly Ala Gly Lys Ser Ser Leu Thr |      |      |
| 1330  | 1335 | 1340 |
| Asn Cys Leu Phe Arg Ile Leu Glu Ala Ala Gly Gly Gln Ile Ile Ile |      |      |
| 1345  | 1350 | 1355 |
| Asp Gly Val Asp Ile Ala Ser Ile Gly Leu His Asp Leu Arg Glu Lys |      |      |
| 1365  | 1370 | 1375 |
| Leu Thr Ile Ile Pro Gln Asp Pro Ile Leu Phe Ser Gly Ser Leu Arg |      |      |
| 1380  | 1385 | 1390 |
| Met Asn Leu Asp Pro Phe Asn Asn Tyr Ser Asp Glu Glu Ile Trp Lys |      |      |
| 1395  | 1400 | 1405 |
| Ala Leu Glu Leu Ala His Leu Lys Ser Phe Val Ala Ser Leu Gln Leu |      |      |
| 1410  | 1415 | 1420 |
| Gly Leu Ser His Glu Val Thr Glu Ala Gly Gly Asn Leu Ser Ile Gly |      |      |
| 1425  | 1430 | 1435 |
| Gln Arg Gln Leu Leu Cys Leu Gly Arg Ala Leu Leu Arg Lys Ser Lys |      |      |
| 1445  | 1450 | 1455 |
| Ile Leu Val Leu Asp Glu Ala Thr Ala Ala Val Asp Leu Glu Thr Asp |      |      |
| 1460  | 1465 | 1470 |
| Asn Leu Ile Gln Thr Thr Ile Gln Asn Glu Phe Ala His Cys Thr Val |      |      |
| 1475  | 1480 | 1485 |
| Ile Thr Ile Ala His Arg Leu His Thr Ile Met Asp Ser Asp Lys Val |      |      |
| 1490  | 1495 | 1500 |
| Met Val Leu Asp Asn Gly Lys Ile Ile Glu Cys Gly Ser Pro Glu Glu |      |      |
| 1505  | 1510 | 1515 |
| Leu Leu Gln Ile Pro Gly Pro Phe Tyr Phe Met Ala Lys Glu Ala Gly |      |      |
| 1525  | 1530 | 1535 |

Ile Glu Asn Val Asn Ser Thr Lys Phe  
1540 1545

<210> 3  
<211> 184  
<212> DNA  
<213> Homo sapiens

<400> 3  
aacttacttc tcattcttgc tccttgccag gcaccctggg tgactgataa gaggcctccg 60  
ccagattggc ccagcaaagg caagatccag tttaacaact accaagtgcg gtaccgacct 120  
gagctggatc tggtcctcag agggatcact tgtgacatcg gtagcatgga gaaggtaggt 180  
ggag 184



**FIG. 1**







FIG. 2



030504

16369 U.S. PTO

PTO/SB/16 (08-03)

Approved for use through 07/31/2006. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 414834592 US

| INVENTOR(S)  |  |  |  |   |  |
|--|--|--|--|---|--|
| Given Name (first and middle [if any])   |  | Family Name or Surname   |  | Residence<br>(City and either State or Foreign Country) |  |
| Mark J.  |  | Ratain   |  | Chicago, IL   |  |
| Additional inventors are being named on the <u>1</u> separately numbered sheets attached hereto  |  |  |  |   |  |
| TITLE OF THE INVENTION (500 characters max)  |  |  |  |   |  |
| Methods and Compositions Relating to the Pharmacogenetics of ABCC2 Gene Variants   |  |  |  |   |  |
| Direct all correspondence to: CORRESPONDENCE ADDRESS   |  |  |  |   |  |
| <input checked="" type="checkbox"/> Customer Number: <div style="border: 1px solid black; padding: 5px; display: inline-block;">32425</div>  |  |  |  |   |  |
| OR   |  |  |  |   |  |
| <input type="checkbox"/> Firm or Individual Name   |  |  |  |   |  |
| Address  |  |  |  |   |  |
| Address  |  |  |  |   |  |
| City   |  | State  |  | Zip   |  |
| Country  |  | Telephone  |  | Fax   |  |
| ENCLOSED APPLICATION PARTS (check all that apply)  |  |  |  |   |  |
| <input checked="" type="checkbox"/> Specification Number of Pages <u>57 + 12-pg. sequence listing</u>  |  | <input checked="" type="checkbox"/> CD(s), Number <u>1</u>   |  |   |  |
| <input checked="" type="checkbox"/> Drawing(s) Number of Sheets <u>2</u>   |  | <input checked="" type="checkbox"/> Other (specify) <u>Statement re: sequence listing</u>                                |  |   |  |
| <input type="checkbox"/> Application Date Sheet. See 37 CFR 1.76   |  | (w/paper copy & disk); postcard  |  |   |  |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT   |  |  |  |   |  |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.   |  | <div style="border: 1px solid black; padding: 10px; text-align: center;">FILING FEE<br/>Amount (\$)<br/><br/>80.00</div> |  |   |  |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fees.  |  |  |  |   |  |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: <u>50-1212</u>                              |  |  |  |   |  |
| <input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.  |  |  |  |   |  |
| The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.  |  |  |  |   |  |
| <input type="checkbox"/> No.   |  |  |  |   |  |
| <input checked="" type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: <u>National Institutes of Health,</u><br><u>Grant Number GM61393</u> |  |  |  |   |  |

17548 U.S. PTO  
60/550268

030504

[Page 1 of 2]

Respectfully submitted,

Date March 5, 2004

SIGNATURE

TYPED or PRINTED NAME Gina N. ShishimaTELEPHONE 512-536-3081REGISTRATION NO. 45,104

(if appropriate)

Docket Number: ARCD:405USP1**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**PROVISIONAL APPLICATION COVER SHEET**  
Additional Page

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

|               |              |
|---------------|--------------|
| Docket Number | ARCD:405USP1 |
|---------------|--------------|

| INVENTOR(S)/APPLICANT(S)               |                   |   |
|--|-------------------|---|
| Given Name (first and middle [if any]) | Family or Surname | Residence<br>(City and either State or Foreign Country) |
| Federico                               | Innocenti         | Chicago, IL   |
| Deanna L.                              | Kroetz            | San Francisco, CA                                       |
| Samir                                  | Undevia           | Chicago, IL   |

Number 2 of 2

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**